JP2016113367A - Method for producing liquid composition - Google Patents
Method for producing liquid composition Download PDFInfo
- Publication number
- JP2016113367A JP2016113367A JP2014250414A JP2014250414A JP2016113367A JP 2016113367 A JP2016113367 A JP 2016113367A JP 2014250414 A JP2014250414 A JP 2014250414A JP 2014250414 A JP2014250414 A JP 2014250414A JP 2016113367 A JP2016113367 A JP 2016113367A
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- diketopiperazine
- purine
- tyr
- exchange resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 306
- 239000000203 mixture Substances 0.000 title claims abstract description 291
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 43
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 262
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims abstract description 142
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 80
- 239000003729 cation exchange resin Substances 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 150000003212 purines Chemical class 0.000 claims description 36
- 239000000049 pigment Substances 0.000 claims description 31
- 239000000356 contaminant Substances 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 23
- 241000196324 Embryophyta Species 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- 244000269722 Thea sinensis Species 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 108010035532 Collagen Proteins 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- CHYMARRIVIIBNV-UWVGGRQHSA-N (3S,6S)-3-(4-Hydroxybenzyl)-6-(hydroxymethyl)-2,5-piperazinedione Chemical compound N1C(=O)[C@H](CO)NC(=O)[C@@H]1CC1=CC=C(O)C=C1 CHYMARRIVIIBNV-UWVGGRQHSA-N 0.000 claims description 7
- GENSLUDVKWKQMX-STQMWFEESA-N (3s,6s)-3-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)piperazine-2,5-dione Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CC1=CC=C(O)C=C1 GENSLUDVKWKQMX-STQMWFEESA-N 0.000 claims description 7
- LMDVFSHGYANGRP-UHFFFAOYSA-N 3-[(4-hydroxyphenyl)methyl]-6-propan-2-ylpiperazine-2,5-dione Chemical compound N1C(=O)C(C(C)C)NC(=O)C1CC1=CC=C(O)C=C1 LMDVFSHGYANGRP-UHFFFAOYSA-N 0.000 claims description 7
- QHLSAVHDWSYPEP-UHFFFAOYSA-N 3-[(4-hydroxyphenyl)methyl]piperazine-2,5-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NCC(=O)N1 QHLSAVHDWSYPEP-UHFFFAOYSA-N 0.000 claims description 7
- GENSLUDVKWKQMX-UHFFFAOYSA-N 9-Acetyl-10-deacetylspicataxine Natural products N1C(=O)C(CC(C)C)NC(=O)C1CC1=CC=C(O)C=C1 GENSLUDVKWKQMX-UHFFFAOYSA-N 0.000 claims description 7
- KDAHZWKHYACWHQ-XDTLVQLUSA-N Cyclo-(Leu-Tyr) Natural products O=C1[C@H]([C@H](CC)C)NC(=O)[C@H](Cc2ccc(O)cc2)N1 KDAHZWKHYACWHQ-XDTLVQLUSA-N 0.000 claims description 7
- MUFXDFWAJSPHIQ-XDTLVQLUSA-N Ile-Tyr Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 MUFXDFWAJSPHIQ-XDTLVQLUSA-N 0.000 claims description 7
- GRWVBLRIPRGGPD-UHFFFAOYSA-N cYF Natural products C1=CC(O)=CC=C1CC1C(=O)NC(CC=2C=CC=CC=2)C(=O)N1 GRWVBLRIPRGGPD-UHFFFAOYSA-N 0.000 claims description 7
- NGPCLOGFGKJCBP-UHFFFAOYSA-N cYY Natural products C1=CC(O)=CC=C1CC1C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)N1 NGPCLOGFGKJCBP-UHFFFAOYSA-N 0.000 claims description 7
- GRWVBLRIPRGGPD-HOTGVXAUSA-N cyclo(L-tyrosyl-L-phenylalanyl) Chemical compound C1=CC(O)=CC=C1C[C@H]1C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1 GRWVBLRIPRGGPD-HOTGVXAUSA-N 0.000 claims description 7
- NGPCLOGFGKJCBP-HOTGVXAUSA-N cyclo(L-tyrosyl-L-tyrosyl) Chemical compound C1=CC(O)=CC=C1C[C@H]1C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1 NGPCLOGFGKJCBP-HOTGVXAUSA-N 0.000 claims description 7
- 108010030615 cyclo(leucyl-tyrosyl) Proteins 0.000 claims description 7
- 108010012664 cyclo(seryltyrosyl) Proteins 0.000 claims description 7
- 108010053287 cyclo(tyrosyl-tyrosyl) Proteins 0.000 claims description 7
- 108010044374 isoleucyl-tyrosine Proteins 0.000 claims description 7
- 235000020712 soy bean extract Nutrition 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 abstract description 6
- 235000010469 Glycine max Nutrition 0.000 description 148
- 244000068988 Glycine max Species 0.000 description 136
- 229920005989 resin Polymers 0.000 description 66
- 239000011347 resin Substances 0.000 description 66
- 229920001429 chelating resin Polymers 0.000 description 44
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 25
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 239000012153 distilled water Substances 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 235000013361 beverage Nutrition 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 235000013616 tea Nutrition 0.000 description 17
- 239000000872 buffer Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 12
- BFMNXKXZDPXHIG-OLOZJIBXSA-N 2-chloro-3-[(e,7r,11r)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(Cl)C(=O)C2=C1 BFMNXKXZDPXHIG-OLOZJIBXSA-N 0.000 description 11
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 11
- 238000000354 decomposition reaction Methods 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 239000003957 anion exchange resin Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- -1 cyclic organic compound Chemical class 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 125000000962 organic group Chemical group 0.000 description 8
- 229940116269 uric acid Drugs 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 7
- 239000003456 ion exchange resin Substances 0.000 description 7
- 229920003303 ion-exchange polymer Polymers 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010016626 Dipeptides Proteins 0.000 description 6
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 6
- 229960000643 adenine Drugs 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 235000013405 beer Nutrition 0.000 description 6
- 229940023913 cation exchange resins Drugs 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000012607 strong cation exchange resin Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000013334 alcoholic beverage Nutrition 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229910003460 diamond Inorganic materials 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 4
- 235000021577 malt beverage Nutrition 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- 229940075420 xanthine Drugs 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 239000004278 EU approved seasoning Substances 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 239000012468 concentrated sample Substances 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 235000019583 umami taste Nutrition 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- FYGHPRWSAALUHI-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione;7h-purine Chemical compound C1=NC=C2NC=NC2=N1.O=C1NC(=O)NC2=C1NC=N2 FYGHPRWSAALUHI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001058 brown pigment Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019225 fermented tea Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002212 purine nucleoside Substances 0.000 description 2
- 239000002213 purine nucleotide Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000012608 weak cation exchange resin Substances 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- NQXUYGGCWWRWBP-LBPRGKRZSA-N (2s)-2-[(1-aminocyclopentanecarbonyl)amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(N)CCCC1 NQXUYGGCWWRWBP-LBPRGKRZSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- YMVDTXSRLFAIKI-UHFFFAOYSA-N 7h-purine Chemical compound C1=NC=C2NC=NC2=N1.C1=NC=C2NC=NC2=N1 YMVDTXSRLFAIKI-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical compound [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010050181 aleurone Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Abstract
Description
本発明は、液状組成物の製造方法に関する。具体的には、本発明は、ジケトピペラジン及びプリン体を含有する液状組成物から、プリン体の含有量を選択的に低減させたジケトピペラジン含有液状組成物を製造する方法、当該方法により製造されるジケトピペラジン含有液状組成物、及びジケトピペラジン、プリン体及び色素を含有する液状組成物からプリン体及び色素夾雑物の含有量を低減する方法に関する。 The present invention relates to a method for producing a liquid composition. Specifically, the present invention provides a method for producing a diketopiperazine-containing liquid composition in which the content of purine is selectively reduced from a liquid composition containing diketopiperazine and purine, and the method. The present invention relates to a diketopiperazine-containing liquid composition to be produced, and a method for reducing the contents of purine bodies and pigment impurities from a liquid composition containing diketopiperazine, a purine body and a pigment.
アミノ酸が二つ結合した「ジペプチド」が機能性物質として注目されている。ジペプチドは単体アミノ酸にない物理的性質や新たな機能を付加することが可能であり、アミノ酸以上の応用範囲を有するものとして期待されている。特に、環状ジペプチドであるジケトピペラジンは、抗菌作用や抗酸化作用（非特許文献１，２）、学習意欲改善作用（特許文献１）などの様々な生理活性を持つことが知られており、医療・薬理分野において需要が拡大することが予想されている。 A “dipeptide” in which two amino acids are bonded has attracted attention as a functional substance. Dipeptides can add physical properties and new functions not found in simple amino acids, and are expected to have a range of applications beyond amino acids. In particular, diketopiperazine, which is a cyclic dipeptide, is known to have various physiological activities such as antibacterial action and antioxidant action (Non-patent Documents 1 and 2), learning motivation improving action (Patent Document 1), Demand is expected to expand in the medical and pharmacological fields.
通常、ジケトピペラジンは、当該分野で公知の方法に従って調製することができる。例えば、化学合成法（非特許文献３）や酵素法（非特許文献２，４）などで製造されている。また、直鎖ペプチドを超臨界領域又は亜臨界領域にある高温高圧水で脱水・環化反応させることにより、任意のアミノ酸配列を持った環状ペプチドを合成する方法（特許文献２）、直鎖ジペプチド又は直鎖トリペプチドを水溶媒中で加熱処理して環状ジペプチドを製造する方法（特許文献３，４）も提案されている。また、非特許文献５には、タンパク質やペプチドの加熱処理及び／又は酵素処理によりジケトピペラジンが生成すること、及びカゼインや大豆タンパク質の部分加水分解物中にジケトピペラジンが含まれることが開示されている。 In general, diketopiperazine can be prepared according to methods known in the art. For example, it is manufactured by a chemical synthesis method (Non-Patent Document 3), an enzymatic method (Non-Patent Documents 2 and 4), or the like. In addition, a method of synthesizing a cyclic peptide having an arbitrary amino acid sequence by dehydrating and cyclizing a linear peptide with high-temperature and high-pressure water in a supercritical region or a subcritical region (Patent Document 2), linear dipeptide Alternatively, a method for producing a cyclic dipeptide by heat-treating a linear tripeptide in an aqueous solvent (Patent Documents 3 and 4) has also been proposed. Non-Patent Document 5 discloses that diketopiperazine is produced by heat treatment and / or enzymatic treatment of proteins and peptides, and that diketopiperazine is contained in a casein or soy protein partial hydrolyzate. Has been.
タンパク質を多量に含む動植物由来原料からジケトピペラジン含有液状組成物を製造する場合、その製造過程でプリン体や色素夾雑物などの夾雑物がジケトピペラジン含有液状組成物中に混入する場合がある。特に、プリン体は食品の旨味成分として知られており、肉類、魚介類、野菜・穀物などの動植物製品に多く含まれている。このプリン体は肝臓で代謝されて尿酸となるが、血液中の尿酸値が一定値以上となると高尿酸血症になり、さらに結晶化した尿酸が関節に蓄積すると痛風になる。そのため、様々な生理活性を有するジケトピペラジンを含みつつ、プリン体量が抑えられた飲食品に対する消費者の期待が高まっている。 When producing a diketopiperazine-containing liquid composition from animal or plant-derived materials containing a large amount of protein, impurities such as purines and pigment contaminants may be mixed in the diketopiperazine-containing liquid composition during the production process. . In particular, purines are known as umami ingredients of foods, and are abundant in animal and plant products such as meat, seafood, vegetables and grains. This purine is metabolized in the liver to become uric acid. However, when the uric acid level in the blood exceeds a certain value, hyperuricemia occurs, and when crystallized uric acid accumulates in the joint, it becomes gouty. Therefore, consumers' expectations for foods and drinks in which the amount of purine is suppressed while containing diketopiperazine having various physiological activities are increasing.
プリン体は過剰摂取により高尿酸血症や痛風の発症の可能性が高まることが知られているため、プリン体量が抑えられた飲食品が求められている。ところが、環状ジペプチドであるジケトピペラジンを含有する液状組成物について、ジケトピペラジン含有量の低下を抑えつつ、プリン体を選択的に除去する技術については未だ知られていない。 Since purine bodies are known to increase the possibility of hyperuricemia and gout due to excessive intake, foods and drinks with reduced purine bodies are required. However, regarding a liquid composition containing diketopiperazine, which is a cyclic dipeptide, a technique for selectively removing purines while suppressing a decrease in diketopiperazine content is not yet known.
本発明の課題は、ジケトピペラジン及びプリン体を含有する液状組成物から、プリン体の含有量の少ないジケトピペラジン含有液状組成物を製造する方法を提供することにある。 An object of the present invention is to provide a method for producing a diketopiperazine-containing liquid composition having a small purine content from a liquid composition containing a diketopiperazine and a purine body.
本発明者らは、上記課題を解決するために鋭意検討を行った結果、ジケトピペラジン及びプリン体を含有する液状組成物を陽イオン交換樹脂と接触させ、その後、ジケトピペラジン含有液を回収することで、液状組成物中のジケトピペラジン含有量の低下は抑えられる一方、プリン体の含有量が低減されたジケトピペラジン含有液状組成物を得ることができることを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventors contacted a liquid composition containing a diketopiperazine and a purine body with a cation exchange resin, and then recovered the diketopiperazine-containing liquid. By doing so, it is found that a diketopiperazine-containing liquid composition having a reduced purine content can be obtained while the decrease in the diketopiperazine content in the liquid composition is suppressed, and the present invention is completed. It came to.
即ち、本発明は、以下に関する。
１）．ジケトピペラジン及びプリン体を含有する液状組成物と陽イオン交換樹脂とを接触させる接触工程、及び
前記接触工程後にジケトピペラジン含有液を回収する回収工程を含み、
前記接触工程における陽イオン交換樹脂と前記液状組成物との容積比率（陽イオン交換樹脂の容積：前記液状組成物の容積）が１：０．５〜１：１０であり、
前記接触工程において用いるジケトピペラジン及びプリン体を含有する液状組成物のｐＨが２．０〜６．０である、
ジケトピペラジン含有液状組成物の製造方法。
２）．陽イオン交換樹脂と前記液状組成物との容積比率（陽イオン交換樹脂の容積：前記液状組成物の容積）が１：１〜１：５である、１）に記載の製造方法。
３）．前記接触工程において用いるジケトピペラジン及びプリン体を含有する液状組成物のｐＨが３．５〜５．８である、１）又は２）に記載の製造方法。
４）．前記接触工程において用いるジケトピペラジン及びプリン体を含有する液状組成物が色素を含む、１）〜３）のいずれかに記載の製造方法。
５）．前記接触工程において用いるジケトピペラジン及びプリン体を含有する前記液状組成物中に含まれるジケトピペラジンが、シクロセリルチロシン〔Cyclo(Ser-Tyr)〕、シクロアスパラギニルチロシン〔Cyclo(Asn-Tyr)〕、シクロチロシルグリシン〔Cyclo(Tyr-Gly)〕、シクロチロシルチロシン〔Cyclo(Tyr-Tyr)〕、シクロロイシルチロシン〔Cyclo(Leu-Tyr)〕、シクロバリルチロシン〔Cyclo(Val-Tyr)〕、シクロイソロイシルチロシン〔Cyclo(Ile-Tyr)〕、及びシクロフェニルアラニルチロシン〔Cyclo(Phe-Tyr)〕からなる群から選択される１つ又は２つ以上を含むものである、１）〜４）のいずれかに記載の製造方法。
６）．前記接触工程において用いるジケトピペラジン及びプリン体を含有する前記液状組成物が、動植物由来原料を１００〜１７０℃の液体中で３０分〜数時間加熱したものである、１）〜５）のいずれかに記載の製造方法。
７）．前記動植物由来原料が、大豆エキス、茶エキス、麦芽エキス、及びコラーゲンペプチドからなる群から選択される、６）に記載の製造方法。
８）．前記接触工程の前に、ジケトピペラジン及びプリン体を含有する液状組成物と水とを混合する混合工程を含む、１）〜７）のいずれかに記載の製造方法。
９）．１）〜８）のいずれかに記載の製造方法により得られるジケトピペラジン含有液状組成物であって、
Ｂｒｉｘあたりのジケトピペラジンの総量が、１０００μｇ／１００ｇ／Ｂｒｉｘ以上である、前記ジケトピペラジン含有液状組成物。
１０）．プリン体の総量に対するジケトピペラジンの総量の比率（ジケトピペラジンの総量／プリン体の総量）が、３．５以上である、９）に記載のジケトピペラジン含有液状組成物。
１１）．ジケトピペラジン、プリン体及び色素を含有する液状組成物からプリン体及び色素夾雑物の含有量を低減する方法であって、
前記液状組成物と陽イオン交換樹脂とを接触させる接触工程、及び
接触工程後にジケトピペラジン含有液を回収する回収工程を含み、
前記接触工程における陽イオン交換樹脂と前記液状組成物との容積比率（陽イオン交換樹脂の容積：原料エキスの容積）が１：０．５〜１：１０であり、
前記接触工程において用いるジケトピペラジン及びプリン体を含有する液状組成物のｐＨが２．０〜６．０である、
前記方法。
That is, the present invention relates to the following.
1). A contact step of bringing a liquid composition containing a diketopiperazine and purine into contact with a cation exchange resin, and a recovery step of recovering a diketopiperazine-containing liquid after the contact step,
The volume ratio of the cation exchange resin and the liquid composition in the contact step (volume of the cation exchange resin: volume of the liquid composition) is 1: 0.5 to 1:10,
The pH of the liquid composition containing diketopiperazine and purine used in the contacting step is 2.0 to 6.0.
A method for producing a diketopiperazine-containing liquid composition.
2). The production method according to 1), wherein a volume ratio of the cation exchange resin to the liquid composition (a volume of the cation exchange resin: a volume of the liquid composition) is 1: 1 to 1: 5.
3). The production method according to 1) or 2), wherein the pH of the liquid composition containing the diketopiperazine and the purine used in the contact step is 3.5 to 5.8.
4). The production method according to any one of 1) to 3), wherein the liquid composition containing a diketopiperazine and a purine used in the contact step contains a dye.
5). The diketopiperazine contained in the liquid composition containing the diketopiperazine and purine used in the contacting step is cycloseryltyrosine [Cyclo (Ser-Tyr)], cycloasparaginyltyrosine [Cyclo (Asn-Tyr). )], Cyclotyrosylglycine [Cyclo (Tyr-Gly)], Cyclotyrosyltyrosine [Cyclo (Tyr-Tyr)], Cycloleusyltyrosine [Cyclo (Leu-Tyr)], Cyclovalyltyrosine [Cyclo (Val- Tyr)], cycloisoleucyl tyrosine [Cyclo (Ile-Tyr)], and cyclophenylalanyltyrosine [Cyclo (Phe-Tyr)], or one or more selected from the group consisting of ) To 4).
6). Any of 1) to 5), wherein the liquid composition containing diketopiperazine and purine used in the contacting step is obtained by heating an animal and plant-derived material in a liquid at 100 to 170 ° C. for 30 minutes to several hours. The manufacturing method of crab.
7). 6. The production method according to 6), wherein the animal and plant-derived material is selected from the group consisting of soybean extract, tea extract, malt extract, and collagen peptide.
8). The manufacturing method in any one of 1) -7) including the mixing process of mixing the liquid composition containing diketopiperazine and a purine body, and water before the said contact process.
9). A diketopiperazine-containing liquid composition obtained by the production method according to any one of 1) to 8),
The diketopiperazine-containing liquid composition, wherein the total amount of diketopiperazine per Brix is 1000 μg / 100 g / Brix or more.
10). The diketopiperazine-containing liquid composition according to 9), wherein the ratio of the total amount of diketopiperazine to the total amount of purines (total amount of diketopiperazine / total amount of purines) is 3.5 or more.
11). A method for reducing the content of purine and pigment contaminants from a liquid composition containing diketopiperazine, purine and pigment,
A contact step of bringing the liquid composition into contact with the cation exchange resin, and a recovery step of recovering the diketopiperazine-containing liquid after the contact step,
The volume ratio of the cation exchange resin and the liquid composition in the contact step (volume of cation exchange resin: volume of raw material extract) is 1: 0.5 to 1:10,
The pH of the liquid composition containing diketopiperazine and purine used in the contacting step is 2.0 to 6.0.
Said method.
本発明は、医療・薬理分野において需要が拡大することが予想される機能性物質であるジケトピペラジンを高濃度に含有しつつも、プリン体の含有量の少ないジケトピペラジン含有液状組成物を提供できるという優れた効果を奏する。 The present invention provides a diketopiperazine-containing liquid composition containing a small amount of purine, while containing a high concentration of diketopiperazine, which is a functional substance that is expected to expand in the medical / pharmacological field. There is an excellent effect that it can be provided.
本発明の一態様は、ジケトピペラジンを含有しつつも、プリン体の含有量の少ない液状組成物を製造する方法である。具体的には、一定範囲のｐＨ条件下でジケトピペラジン及びプリン体を含有する液状組成物を陽イオン交換樹脂と一定範囲の容積比率で接触させ、その後、ジケトピペラジン含有液を回収することで、プリン体の含有量が低減されたジケトピペラジン含有液状組成物を製造する方法である。また、液状組成物と陽イオン交換樹脂とを接触させる前に、動植物由来原料を一定範囲の温度かつ一定範囲の時間で加熱処理し、ジケトピペラジン及びプリン体を含有する液状組成物を調製する工程を含んでいてもよく、さらに調製された液状組成物を陽イオン交換樹脂と接触させる前に水と混合する工程を含んでいてもよい。なお、本明細書において、ジケトピペラジン又はその塩をまとめて、単に、ジケトピペラジンと称する場合がある。 One embodiment of the present invention is a method for producing a liquid composition containing a diketopiperazine and having a low purine content. Specifically, a liquid composition containing a diketopiperazine and a purine body is brought into contact with a cation exchange resin at a volume ratio in a certain range under a certain range of pH conditions, and then the diketopiperazine-containing liquid is recovered. The method for producing a diketopiperazine-containing liquid composition having a reduced purine content. Also, before bringing the liquid composition into contact with the cation exchange resin, the animal and plant-derived material is heat-treated at a certain range of temperature and for a certain range of time to prepare a liquid composition containing diketopiperazine and purine. A step may be included, and a step of mixing the prepared liquid composition with water before contacting with the cation exchange resin may be included. In the present specification, diketopiperazine or a salt thereof may be collectively referred to simply as diketopiperazine.
１．ジケトピペラジン及びプリン体を含有する液状組成物
本明細書において「ジケトピペラジン及びプリン体を含有する液状組成物」とは、少なくともジケトピペラジン、プリン体及び水とを含む組成物をいう。ジケトピペラジン、プリン体及び水を含む場合、水にジケトピペラジンとプリン体を混合させたものでも、あるいはジケトピペラジン、プリン体及び水を含む各種の液状組成物でも、あるいは、動植物由来原料に分解（一例として酵素処理及び／又は加熱処理）・抽出処理等を施した結果得られた処理物であってもよい。混合比や、エキスの種類、動植物由来原料の種類によって、液状組成物中のジケトピペラジンの組成及び含有量は異なる。本発明で使用される、ジケトピペラジン及びプリン体を含有する液状組成物の製造方法は特に限定されるものではない。また、後述する接触工程の前に、さらに水と混合する工程を含み、濃度調整を行ってもよい。
1. Liquid Composition Containing Diketopiperazine and Purine Body In the present specification, the “liquid composition containing diketopiperazine and purine body” refers to a composition containing at least diketopiperazine, purine body and water. In the case of containing diketopiperazine, purine and water, it may be a mixture of diketopiperazine and purine in water, various liquid compositions containing diketopiperazine, purine and water, or animal and plant-derived materials It may be a processed product obtained as a result of performing decomposition (enzyme treatment and / or heat treatment as an example), extraction treatment, and the like. The composition and content of diketopiperazine in the liquid composition vary depending on the mixing ratio, the type of extract, and the type of animal or plant-derived raw material. The method for producing the liquid composition containing diketopiperazine and purine used in the present invention is not particularly limited. Moreover, before the contact process mentioned later, the process of mixing with water may be included and density | concentration adjustment may be performed.
１−１．ジケトピペラジン
本明細書でいうジケトピペラジンとは、アミノ酸のアミノ基とカルボキシル基とが脱水縮合することにより生成した環状有機化合物のことをいう。尚、本明細書において、ジケトピペラジンのアミノ酸の構成が同じであれば、それらの記載順序はいずれが先でも構わなく、例えば、〔Cyclo(Pro-Hyp)〕と〔Cyclo(Hyp-Pro)〕は同じジケトピペラジンを表すものである。
1-1. Diketopiperazine As used herein, diketopiperazine refers to a cyclic organic compound produced by dehydration condensation of an amino group and a carboxyl group of an amino acid. In the present specification, as long as the amino acid composition of diketopiperazine is the same, any order may be used, for example, [Cyclo (Pro-Hyp)] and [Cyclo (Hyp-Pro)]. ] Represents the same diketopiperazine.
本発明で使用される液状組成物中に含まれるジケトピペラジンは特に限定されるものではない。例えば、本発明で使用される液状組成物中に含まれるジケトピペラジンとしては、チロシン含有ジケトピペラジン（Tyr-DKPs）が挙げられる。Tyr-DKPsとしては、シクロセリルチロシン〔Cyclo(Ser-Tyr)〕、シクロアスパラギニルチロシン〔Cyclo(Asn-Tyr)〕、シクロチロシルグリシン〔Cyclo(Tyr-Gly)〕、シクロチロシルチロシン〔Cyclo(Tyr-Tyr)〕、シクロロイシルチロシン〔Cyclo(Leu-Tyr)〕、シクロバリルチロシン〔Cyclo(Val-Tyr)〕、シクロイソロイシルチロシン〔Cyclo(Ile-Tyr)〕、シクロフェニルアラニルチロシン〔Cyclo(Phe-Tyr)〕などが例示されるが、こられに限定されるものではない。 The diketopiperazine contained in the liquid composition used in the present invention is not particularly limited. For example, examples of the diketopiperazine contained in the liquid composition used in the present invention include tyrosine-containing diketopiperazines (Tyr-DKPs). Tyr-DKPs include cycloseryltyrosine [Cyclo (Ser-Tyr)], cycloasparaginyltyrosine [Cyclo (Asn-Tyr)], cyclotyrosylglycine [Cyclo (Tyr-Gly)], cyclotyrosyltyrosine [ Cyclo (Tyr-Tyr)], cycloleucyltyrosine [Cyclo (Leu-Tyr)], cyclovalyltyrosine [Cyclo (Val-Tyr)], cycloisoleucine tyrosine [Cyclo (Ile-Tyr)], cyclophenylaratyr Nyltyrosine [Cyclo (Phe-Tyr)] and the like are exemplified, but not limited thereto.
１−２．プリン体
本明細書において「プリン体」とは、プリン環を基本骨格とする生体物質で、核酸又はアルカロイドの塩基性物質である。核酸中に多く含まれるため細胞数の多い組織、細胞分裂の盛んな組織に多く存在する。食品中では旨味の成分として知られており、肉類、魚介類、野菜・穀物などの動植物製品に多く含まれている。プリン体は肝臓で代謝されて尿酸となるが、血液中の尿酸値が一定値以上となると高尿酸血症になり、さらに結晶化した尿酸が関節に蓄積すると痛風になる。そのため、従来のビール等が有する旨味等を保持した、低糖・低カロリー発酵麦芽飲料に加えて、低プリン体発酵麦芽飲料に対する消費者の期待が高まっている。プリン体には、遊離プリン塩基、プリンヌクレオチド、プリンヌクレオシド及び高分子核酸が含まれる。遊離プリン塩基には、プリン、アデニン、グアニン、ヒポキサンチン、キサンチン、テオブロミン、カフェイン、尿酸、イソグアニン等が含まれる。また、プリンヌクレオチドとは、プリンヌクレオシドの糖部分がリン酸とエステルを作っている化合物の総称であり、アデニル酸、イノシン酸、グアニル酸等が含まれる。さらに、プリンヌクレオシドとは、プリン塩基と糖の還元基とがＮ−グリコシド結合した配糖体化合物の総称であり、アデノシン、イノシン、グアノシン等が含まれる。本発明において低減されるプリン体は特に限定されるものではないが、好ましくは液状組成物中のプリン、アデニン、グアニン、ヒポキサンチン、キサンチン、テオブロミン、カフェイン、尿酸、及びイソグアニンの含有量が低減され、より好ましくはアデニン、グアニン、ヒポキサンチン、及びキサンチンの含有量が低減される。
1-2. Purine body In this specification, the "purine body" is a biological substance having a purine ring as a basic skeleton, and is a basic substance of nucleic acid or alkaloid. Because it is contained in many nucleic acids, it is present in many tissues with many cells and actively divided cells. It is known as an umami ingredient in foods and is abundant in animal and plant products such as meat, seafood, vegetables and grains. Purines are metabolized in the liver to become uric acid, but when the uric acid level in the blood exceeds a certain value, hyperuricemia occurs, and when crystallized uric acid accumulates in the joint, it becomes gouty. Therefore, in addition to low sugar and low calorie fermented malt beverages that retain the umami of conventional beers and the like, consumer expectations for low purine fermented malt beverages are increasing. Purine bodies include free purine bases, purine nucleotides, purine nucleosides, and high molecular nucleic acids. Free purine bases include purine, adenine, guanine, hypoxanthine, xanthine, theobromine, caffeine, uric acid, isoguanine and the like. Purine nucleotide is a general term for compounds in which the sugar moiety of purine nucleoside forms an ester with phosphoric acid, and includes adenylic acid, inosinic acid, guanylic acid and the like. Furthermore, a purine nucleoside is a general term for a glycoside compound in which a purine base and a sugar reducing group are N-glycosidically bonded, and includes adenosine, inosine, guanosine and the like. The purine body to be reduced in the present invention is not particularly limited, but preferably the contents of purine, adenine, guanine, hypoxanthine, xanthine, theobromine, caffeine, uric acid, and isoguanine in the liquid composition are reduced. More preferably, the content of adenine, guanine, hypoxanthine, and xanthine is reduced.
本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物中に含まれるジケトピペラジンの総量に限定はないが、好ましくは、１μｇ／１００ｇ／Ｂｒｉｘ以上、より好ましくは１０μｇ／１００ｇ／Ｂｒｉｘ以上、さらにより好ましくは１００μｇ／１００ｇ／Ｂｒｉｘ以上、最も好ましくは１０００μｇ／１００ｇ／Ｂｒｉｘ以上である。 The total amount of diketopiperazine contained in the liquid composition containing the diketopiperazine and purine used in the present invention is not limited, but preferably 1 μg / 100 g / Brix or more, more preferably 10 μg / 100 g / Brix or more, even more preferably 100 μg / 100 g / Brix or more, most preferably 1000 μg / 100 g / Brix or more.
本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物中に含まれるチロシン含有ジケトピペラジン（Tyr-DKPs）の総量に限定はないが、好ましくは１μｇ／１００ｇ／Ｂｒｉｘ以上、より好ましくは１０μｇ／１００ｇ／Ｂｒｉｘ以上、さらにより好ましくは２０μｇ／１００ｇ／Ｂｒｉｘ以上、最も好ましくは１００μｇ／１００ｇ／Ｂｒｉｘ以上である。 The total amount of tyrosine-containing diketopiperazines (Tyr-DKPs) contained in the liquid composition containing diketopiperazine and purine used in the present invention is not limited, but preferably 1 μg / 100 g / Brix or more, more It is preferably 10 μg / 100 g / Brix or more, more preferably 20 μg / 100 g / Brix or more, and most preferably 100 μg / 100 g / Brix or more.
さらに、本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物に含まれるシクロセリルチロシン〔Cyclo(Ser-Tyr)〕、シクロアスパラギニルチロシン〔Cyclo(Asn-Tyr)〕、シクロチロシルグリシン〔Cyclo(Tyr-Gly)〕、シクロチロシルチロシン〔Cyclo(Tyr-Tyr)〕、シクロロイシルチロシン〔Cyclo(Leu-Tyr)〕、シクロバリルチロシン〔Cyclo(Val-Tyr)〕、シクロイソロイシルチロシン〔Cyclo(Ile-Tyr)〕、及びシクロフェニルアラニルチロシン〔Cyclo(Phe-Tyr)〕の総量に限定はないが、好ましくは１μｇ／１００ｇ／Ｂｒｉｘ以上、より好ましくは１０μｇ／１００ｇ／Ｂｒｉｘ以上、さらにより好ましくは２０μｇ／１００ｇ／Ｂｒｉｘ以上、最も好ましくは８０μｇ／１００ｇ／Ｂｒｉｘ以上である。 Furthermore, cycloseryltyrosine [Cyclo (Ser-Tyr)], cycloasparaginyltyrosine [Cyclo (Asn-Tyr)], cyclohexane contained in the liquid composition containing diketopiperazine and purine used in the present invention. Tyrosylglycine (Cyclo (Tyr-Gly)), cyclotyrosyl tyrosine (Cyclo (Tyr-Tyr)), cycloleusyl tyrosine (Cyclo (Leu-Tyr)), cyclovalyltyrosine (Cyclo (Val-Tyr)), The total amount of cycloisoleucyl tyrosine [Cyclo (Ile-Tyr)] and cyclophenylalanyl tyrosine [Cyclo (Phe-Tyr)] is not limited, but is preferably 1 μg / 100 g / Brix or more, more preferably 10 μg / 100 g / Brix or more, even more preferably 20 μg / 100 g / Brix or more, and most preferably 80 μg / 100 g / Brix or more.
本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物としては、特に限定はないが、動植物由来原料を処理して得られる液状組成物が好ましく、動植物由来原料として大豆エキス、茶エキス、麦芽エキス、コラーゲンペプチドが特に好ましい。以下、これら動植物由来原料について詳述する。これらの動植物由来原料は複数の原料を混合して用いてもよい。 The liquid composition containing diketopiperazine and purine used in the present invention is not particularly limited, but a liquid composition obtained by treating animal and plant-derived raw materials is preferable. Extracts, malt extracts and collagen peptides are particularly preferred. Hereinafter, these animal and plant-derived materials will be described in detail. These animal and plant-derived materials may be used by mixing a plurality of materials.
１−３．大豆エキス
本明細書でいう「大豆エキス」とは、大豆を抽出処理又はミリング処理して得られる液体をいう。原料となる大豆（学名：Glycine max）は品種や産地などの制限なく用いることができ、粉砕品などの加工品段階のものを用いることもできる。また、本明細書でいう大豆エキスには、大豆タンパク分解物に加水して得られる液体も便宜上含まれるものとする。
1-3. Soybean extract As used herein, “soybean extract” refers to a liquid obtained by extracting or milling soybeans. Soybeans (scientific name: Glycine max) used as a raw material can be used without restriction of varieties and production areas, and can also be used in processed products such as pulverized products. In addition, the soybean extract referred to in this specification includes a liquid obtained by adding water to a soybean protein degradation product for convenience.
大豆中のタンパク質は、約３割を占めると言われている。大豆タンパク質は、茶タンパク質のように水不溶性タンパク質が多くはないため、水溶性タンパク質を除去する前処理は必須ではなく、必要に応じて行えばよい。水溶性タンパク質を除去する前処理がない場合、ワンポット（One-Pot）反応で、より簡便にジケトピペラジンを高濃度に含有する大豆由来ジケトピペラジン含有液状組成物を製造することができる。 It is said that protein in soybeans accounts for about 30%. Soy protein does not have much water-insoluble protein like tea protein, so pretreatment for removing water-soluble protein is not essential and may be performed as necessary. When there is no pretreatment for removing water-soluble protein, a soybean-derived diketopiperazine-containing liquid composition containing diketopiperazine in a high concentration can be more easily produced by a one-pot reaction.
１−４．茶エキス
本明細書でいう「茶エキス」とは、茶葉を抽出処理して得られる茶抽出物をいう。抽出原料となる茶葉としては、茶樹（学名：Camellia sinensis）を用いて製造された茶葉の葉、茎など、抽出して飲用可能な部位を使用することができる。また、その形態も大葉、粉状など制限されない。茶葉の収穫期についても、所望する香味に合わせて適宜選択できる。
1-4. Tea extract As used herein, “tea extract” refers to a tea extract obtained by extracting tea leaves. As a tea leaf used as an extraction raw material, a tea leaf (scientific name: Camellia sinensis) manufactured tea leaf leaf, stem, etc. that can be extracted and used can be used. Also, the form is not limited to large leaves or powders. The harvest time of tea leaves can also be selected appropriately according to the desired flavor.
本発明で使用される茶エキスは、発酵過程を経ずに製造され、副生成物の含有量が少なく、香味のよいものが好ましい。この香味の観点から、茶エキスの原料となる茶葉は、煎茶、番茶、ほうじ茶、玉露、かぶせ茶、甜茶等の蒸し製の不発酵茶（緑茶）や、嬉野茶、青柳茶、各種中国茶等の釜炒茶等の不発酵茶を用いることが好ましい。 The tea extract used in the present invention is preferably produced without undergoing a fermentation process, has a low content of by-products, and has a good flavor. From this flavor point of view, the tea leaves that are used as the raw material for tea extract are steamed non-fermented tea (green tea) such as Sencha, Bancha, Hojicha, Gyokuro, Kabusecha, Tsujicha, Ureshino tea, Aoyagi tea, various Chinese teas, etc. It is preferable to use non-fermented tea such as Kama-no-chi.
１−５．麦芽エキス
本明細書でいう「麦芽エキス」とは、麦芽又はその粉砕物に抽出処理して得られる抽出物をいう。原料となる麦芽大豆（malt）は、品種や産地などの制限なく用いることができるが、特に大麦の種子を発芽させた大麦麦芽が好適に用いられる。大麦麦芽は、皮部を除去してタンパク質含量の高い画分を分離して用いるのが実用的かつ効率的である。例えば、タンパク質含量の高い画分は、麦芽を表面から徐々に削り、穀皮を除去し、その後、アリューロン層及び胚乳といったタンパク質が多く含まれる画分を削りとる方法が挙げられる。
1-5. Malt extract As used herein, “malt extract” refers to an extract obtained by subjecting malt or a pulverized product thereof to an extraction treatment. Malt soybean (malt) as a raw material can be used without limitation of varieties and production areas, but barley malt obtained by germinating barley seeds is particularly preferably used. For barley malt, it is practical and efficient to remove the skin and separate and use a fraction having a high protein content. For example, the fraction having a high protein content may be a method in which malt is gradually shaved from the surface, the husk is removed, and then a fraction containing a large amount of protein such as an aleurone layer and endosperm is shaved off.
１−６．コラーゲンペプチド
本明細書でいう「コラーゲンペプチド」とは、コラーゲン又はその粉砕物に分解・抽出処理を施して得られる組成物をいう。コラーゲンは動物の結合組織の主要なタンパク質であり、ヒトを含めた哺乳類の身体に最も大量に含まれるタンパク質である。本明細書においてコラーゲンペプチドは特に限定されるものではないが、例えば、コラーゲン又はコラーゲンの酵素処理や熱処理によって得られるものが挙げられる。
1-6. Collagen peptide As used herein, the term “collagen peptide” refers to a composition obtained by subjecting collagen or a pulverized product thereof to decomposition / extraction treatment. Collagen is a major protein in animal connective tissue and is the most abundant protein in mammalian bodies including humans. In the present specification, the collagen peptide is not particularly limited, and examples thereof include collagen or those obtained by enzymatic treatment or heat treatment of collagen.
１−７．動植物由来原料の処理物
本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物は、例えば、動植物由来原料又は動植物原料由来ペプチドを液体中で高温高圧処理することにより得られる。高温高圧処理中の溶媒としては純水（換言すれば、蒸留水）を好適に用いることができるが、これにエタノール等有機溶媒を適宜含有させることもできる。また、抽出溶媒にミネラル分を添加することにより適宜硬度を調整することもできる。加熱処理に供する液体のブリックス（Ｂｒｉｘ）値は、０．１〜５０程度になるように必要に応じて濃縮又は希釈しておくことが好ましい。
1-7. Processed product of animal and plant derived raw material The liquid composition containing the diketopiperazine and purine used in the present invention can be obtained, for example, by subjecting an animal or plant derived raw material or an animal or plant raw material derived peptide to high-temperature and high-pressure treatment in a liquid. Pure water (in other words, distilled water) can be suitably used as the solvent during the high-temperature and high-pressure treatment, but an organic solvent such as ethanol can be appropriately contained therein. Moreover, hardness can also be suitably adjusted by adding a mineral part to an extraction solvent. It is preferable that the Brix value of the liquid to be subjected to the heat treatment is concentrated or diluted as necessary so as to be about 0.1 to 50.
本明細書でいう高温高圧とは、１００℃以上の温度かつ大気圧を越える圧力を意味する。高温高圧抽出装置としては、耐圧性抽出装置や圧力鍋、オートクレーブなどを条件に合わせて用いることができる。 High temperature and high pressure as used in the present specification means a temperature of 100 ° C. or higher and a pressure exceeding atmospheric pressure. As the high-temperature and high-pressure extraction device, a pressure-resistant extraction device, a pressure cooker, an autoclave, or the like can be used according to conditions.
高温高圧処理の温度は、１００〜１７０℃が好ましく、１１０〜１５０℃がより好ましく、１２０〜１４０℃が特に好ましい。尚、この温度は、加熱装置として耐圧性抽出装置を用いた場合には抽出カラムの出口温度を測定した値を示し、加熱装置としてオートクレーブを用いた場合には、圧力容器内の中心温度の温度を測定した値を示す。また、圧力は、０．１０１〜０．７９ＭＰａが好ましく、０．１０１〜０．４８ＭＰａがより好ましい。さらに、加熱時間は３０分〜数時間、好ましくは３０分〜５００分、より好ましくは６０分〜３００分程度である。液体中での高温高圧処理の後、必要に応じて固液分離を行って液部を回収して、ジケトピペラジンを含有する原料エキスが得られる。固液分離には、濾過及び／又は遠心分離手段が用いられる。 The temperature of the high-temperature and high-pressure treatment is preferably 100 to 170 ° C, more preferably 110 to 150 ° C, and particularly preferably 120 to 140 ° C. In addition, this temperature shows the value which measured the exit temperature of an extraction column, when using a pressure-resistant extraction apparatus as a heating apparatus, and when using an autoclave as a heating apparatus, it is the temperature of the center temperature in a pressure vessel. The measured value is shown. The pressure is preferably 0.101 to 0.79 MPa, more preferably 0.101 to 0.48 MPa. Furthermore, the heating time is 30 minutes to several hours, preferably 30 minutes to 500 minutes, more preferably about 60 minutes to 300 minutes. After the high-temperature and high-pressure treatment in the liquid, solid-liquid separation is performed as necessary to recover the liquid portion, and a raw material extract containing diketopiperazine is obtained. Filtration and / or centrifugation means are used for solid-liquid separation.
１−８．ペプチド
本明細書において「ペプチド」とは、動植物由来のタンパク質又はその分解処理物に高温高圧処理、酸又はアルカリ処理、又は酵素処理等を施して低分子化（オリゴペプチド）することで得られる、アミノ酸が数個〜数百個連結したペプチドをいう。
1-8. Peptide In the present specification, the “peptide” is obtained by subjecting a protein derived from animals or plants or a degradation product thereof to high-temperature and high-pressure treatment, acid or alkali treatment, enzyme treatment, etc. to lower the molecular weight (oligopeptide). A peptide in which several to several hundred amino acids are linked.
本発明で使用されるペプチドは、特に限定されないが、例えば、大豆ペプチド、大麦ペプチド、小麦ペプチド、小麦胚芽ペプチド、エンドウペプチド、コメペプチド、コラーゲンペプチドである。また、動植物原料からペプチドを製造して用いてもよいが、市販品を用いてもよい。市販のペプチドとしては、例えばハイニュートＡＭ、ハイニュートＤＣ、ハイニュートＨＫ（以上、不二精油社製）などの大豆ペプチド、オリザペプチドＰ６０（オリザ油化社製）などのコメペプチド、グルタミンペプチドＧＰ−１Ｎ、グルタミンペプチドＧＰ−Ｎ（以上、日清ファルマ社製）などの小麦ペプチド、ゴマペプチドＫＭ−２０（KISCO社製）などのゴマペプチド、ニッピペプチド（ニッピ社製）などのコラーゲンペプチドを例示できる。 Although the peptide used by this invention is not specifically limited, For example, they are soybean peptide, barley peptide, wheat peptide, wheat germ peptide, pea peptide, rice peptide, and collagen peptide. Moreover, although a peptide may be manufactured and used from animal and plant raw materials, a commercial item may be used. Examples of commercially available peptides include soybean peptides such as High New AM, High New DC, and High New HK (above, manufactured by Fuji Seiyaku Co., Ltd.), rice peptides such as Oriza peptide P60 (manufactured by Oriza Oil Chemical Co., Ltd.), and glutamine peptide GP. -1N, wheat peptide such as glutamine peptide GP-N (manufactured by Nisshin Pharma), sesame peptide such as sesame peptide KM-20 (manufactured by KISCO), and collagen peptide such as nippi peptide (manufactured by Nippi) it can.
本発明で使用されるペプチドは、タンパク質を含む動植物由来原料に分解処理を施すことで得られるが、この分解処理はオリゴペプチドが生成される条件下で行う。具体的には、分子量５０００以下のペプチド、好ましくは分子量３０００以下のペプチド、より好ましくは分子量１０００以下のペプチドの割合が高くなるように、分解処理を行う。 The peptide used in the present invention can be obtained by subjecting an animal or plant-derived raw material containing protein to a degradation treatment, and this degradation treatment is performed under conditions under which an oligopeptide is produced. Specifically, the decomposition treatment is performed so that the ratio of peptides having a molecular weight of 5000 or less, preferably peptides having a molecular weight of 3000 or less, more preferably peptides having a molecular weight of 1000 or less is increased.
分解処理は、目的とするオリゴペプチドの生成速度や生成効率等の観点から、高温高圧条件下での分解処理や酵素による分解処理が好適に用いられる。 As the decomposition treatment, from the viewpoint of the production speed and production efficiency of the target oligopeptide, a decomposition treatment under high temperature and high pressure conditions or a decomposition treatment with an enzyme is preferably used.
高温高圧条件下での分解処理を行う場合、タンパク質の焦げを防止するため、溶媒中で行う。溶媒としては、水、エタノール、又はこれらの混合物等を用いるのが好ましく、特に水を用いるのが好ましい。加熱条件は、ペプチドが生成される条件であれば特に限定されない。加熱条件として１００℃以上、さらに１２５℃以上の温度で、３０分〜数時間、好ましくは２時間〜７時間程度の加熱を例示できる。加熱処理装置としては、圧力鍋、オートクレーブなどを条件に合わせて用いることができる。尚、この加熱処理は、液状組成物の製造と同時に行うことができる。 When the decomposition treatment is performed under high temperature and high pressure conditions, it is performed in a solvent in order to prevent the protein from burning. As the solvent, water, ethanol, or a mixture thereof is preferably used, and water is particularly preferably used. The heating condition is not particularly limited as long as the peptide is generated. Examples of the heating conditions include heating at a temperature of 100 ° C. or higher, further 125 ° C. or higher, for 30 minutes to several hours, preferably about 2 to 7 hours. As a heat treatment apparatus, a pressure cooker, an autoclave, etc. can be used according to conditions. In addition, this heat processing can be performed simultaneously with manufacture of a liquid composition.
２．ジケトピペラジン及びプリン体を含有する液状組成物と陽イオン交換樹脂とを接触させる接触工程
本発明の一態様においては、ジケトピペラジン及びプリン体を含有する液状組成物を陽イオン交換樹脂と、一定範囲のｐＨ条件下、かつ一定範囲の容積比率で接触させる。以下、ジケトピペラジン、プリン体、イオン交換樹脂、ｐＨ及び容積比率について詳述する。
2. Contacting step of contacting a liquid composition containing diketopiperazine and purine and a cation exchange resin In one embodiment of the present invention, a liquid composition containing diketopiperazine and purine is used as a cation exchange resin, Contact is performed under a certain range of pH conditions and at a certain volume ratio. Hereinafter, diketopiperazine, purine, ion exchange resin, pH, and volume ratio will be described in detail.
２−１．イオン交換樹脂
本明細書において「イオン交換樹脂」とは、三次元的な網目構造を持った高分子に官能基（イオン交換基）を導入した合成樹脂であり、イオン交換樹脂中の固定イオンと様々な溶液中の対立イオンとの吸着の差を利用することによって、溶液に含まれた各イオンを分離するものである。イオン交換樹脂の高分子基剤としては、スチレン系とアクリル系が一般的で、官能基が酸性を示す陽イオン交換樹脂と、塩基性を示す陰イオン交換樹脂に大別される。さらに導入されるイオン交換基の種類によって、強酸性陽イオン交換樹脂、弱酸性陽イオン交換樹脂、強塩基性陰イオン交換樹脂、弱塩基性陰イオン交換樹脂、重金属イオン等に選択的吸着性を有するキレート樹脂等に分けられる。
2-1. Ion exchange resin In this specification, “ion exchange resin” is a synthetic resin in which a functional group (ion exchange group) is introduced into a polymer having a three-dimensional network structure. Each ion contained in the solution is separated by utilizing the difference in adsorption with the counter ions in the various solutions. The polymer base of the ion exchange resin is generally a styrene type or an acrylic type, and is roughly classified into a cation exchange resin whose functional group is acidic and an anion exchange resin which shows basicity. Furthermore, depending on the type of ion exchange group introduced, selective adsorption to strong acid cation exchange resin, weak acid cation exchange resin, strong base anion exchange resin, weak base anion exchange resin, heavy metal ion, etc. It is divided into the chelate resin which has.
本発明で使用される陽イオン交換樹脂は、官能基が酸性であり溶媒中の陽イオンを吸着できるものであれば、特に限定されず、強酸性陽イオン交換樹脂及び弱酸性陽イオン交換樹脂を好適に使用することができる。このような陽イオン交換樹脂としては、アンバーライトＩＲ１２０Ｂ Ｈ ＡＧ（強陽イオン交換樹脂）、アンバーライトＩＲ １２４Ｈ Ｈ ＡＧ（強陽イオン交換樹脂）、アンバーライト２００ＣＴ Ｈ ＡＧ（強陽イオン交換樹脂）、アンバーライト２５２ＮＡ（強陽イオン交換樹脂）、アンバーライトＩＲＣ７６ＡＧ（弱陽イオン交換樹脂）、アンバーライトＦＰＣ３５００（弱陽イオン交換樹脂）、ダイヤイオンＳＫ１０４（強陽イオン交換樹脂）、ダイヤイオンＳＫ１Ｂ（強陽イオン交換樹脂）、ダイヤイオンＳＫ１１０（強陽イオン交換樹脂）、ダイヤイオンＵＢＫ０８（陽イオン交換樹脂）、ダイヤイオンＵＢＫ１０（陽イオン交換樹脂）、及びダイヤイオンＵＢＫ１２（陽イオン交換樹脂）などが挙げられるが、これらに限定されるものではない。 The cation exchange resin used in the present invention is not particularly limited as long as the functional group is acidic and can adsorb the cation in the solvent, and a strong acid cation exchange resin and a weak acid cation exchange resin are used. It can be preferably used. Examples of such cation exchange resins include Amberlite IR120B H AG (strong cation exchange resin), Amberlite IR 124H H AG (strong cation exchange resin), Amberlite 200CT H AG (strong cation exchange resin), Amberlite 252NA (strong cation exchange resin), Amberlite IRC76AG (weak cation exchange resin), Amberlite FPC3500 (weak cation exchange resin), Diaion SK104 (strong cation exchange resin), Diaion SK1B (strong cation) Ion exchange resin), diamond ion SK110 (strong cation exchange resin), diamond ion UBK08 (cation exchange resin), diamond ion UBK10 (cation exchange resin), and diamond ion UBK12 (cation exchange resin). Is limited to these It is not a thing.
ジケトピペラジン及びプリン体を含有する液状組成物と陽イオン交換樹脂との接触工程の態様は、液状組成物と陽イオン交換樹脂とを接触させることができれば特に限定されるものではない。例えば、ジケトピペラジン及びプリン体を含有する液状組成物に陽イオン交換樹脂を添加・混合することで、液状組成物を陽イオン交換樹脂と接触させることができる。また、陽イオン交換樹脂でカラムを充填し、当該カラムにジケトピペラジン及びプリン体を含有する液状組成物を添加することで、液状組成物を陽イオン交換樹脂と接触させてもよい。 The aspect of the contact process between the liquid composition containing diketopiperazine and purine and the cation exchange resin is not particularly limited as long as the liquid composition and the cation exchange resin can be brought into contact with each other. For example, the liquid composition can be brought into contact with the cation exchange resin by adding and mixing the cation exchange resin to the liquid composition containing diketopiperazine and purine. Alternatively, the liquid composition may be brought into contact with the cation exchange resin by filling the column with a cation exchange resin and adding a liquid composition containing diketopiperazine and purine to the column.
２−２．ｐＨ
本発明において、陽イオン交換樹脂と接触させる液状組成物のｐＨは、本発明の効果を確実かつ効率的に得る観点から、好ましくはｐＨ２．０以上、より好ましくはｐＨ２．５以上、さらにより好ましくはｐＨ３．０、最も好ましくはｐＨ３．５以上であり、好ましくはｐＨ７．０以下、より好ましくはｐＨ６．０以下、さらにより好ましくはｐＨ５．８以下である。また、陽イオン交換樹脂と接触させる液状組成物のｐＨの範囲は、好ましくはｐＨ２．０〜６．０、ｐＨ２．５〜６．０、ｐＨ３．０〜６．０、ｐＨ３．５〜６．０であり、より好ましくはｐＨ３．５〜５．８である。
2-2. pH
In the present invention, the pH of the liquid composition to be brought into contact with the cation exchange resin is preferably pH 2.0 or more, more preferably pH 2.5 or more, and even more preferably from the viewpoint of obtaining the effect of the present invention reliably and efficiently. Is pH 3.0, most preferably pH 3.5 or higher, preferably pH 7.0 or lower, more preferably pH 6.0 or lower, and even more preferably pH 5.8 or lower. The pH range of the liquid composition to be contacted with the cation exchange resin is preferably pH 2.0 to 6.0, pH 2.5 to 6.0, pH 3.0 to 6.0, pH 3.5 to 6. 0, more preferably pH 3.5 to 5.8.
２−３．陽イオン交換樹脂と液状組成物の容積比率
本発明において、陽イオン交換樹脂と接触させる液状組成物の容積比率は、本発明の効果を確実かつ効率的に得る観点から、陽イオン交換樹脂に対する液状組成物の容積比率（陽イオン交換樹脂：液状組成物）が１：０．５〜１：１０であることが好ましく、１：１〜１：５、１：１〜１：２、１：２〜１：５であることがより好ましい。
よって、本発明の製法では、ｐＨを調整し、かつ、陽イオン交換樹脂と液状組成物の容積比率を調整することにより、ジケトピペラジン及びプリン体を含有する液状組成物から選択的にプリン体の含量が選択的に低減された液状組成物を得ることができる。
2-3. Volume ratio of cation exchange resin to liquid composition In the present invention, the volume ratio of the liquid composition to be brought into contact with the cation exchange resin is a liquid ratio to the cation exchange resin from the viewpoint of obtaining the effects of the present invention reliably and efficiently. The volume ratio of the composition (cation exchange resin: liquid composition) is preferably 1: 0.5 to 1:10, and is 1: 1 to 1: 5, 1: 1 to 1: 2, 1: 2. More preferably, it is ˜1: 5.
Therefore, in the production method of the present invention, the purine body is selectively selected from the liquid composition containing diketopiperazine and the purine body by adjusting the pH and adjusting the volume ratio of the cation exchange resin and the liquid composition. A liquid composition with a reduced content of can be obtained.
２−４．色素夾雑物の低減
本発明の一態様においては、プリン体のみならず、色素夾雑物も選択的に低減することができる。本明細書において「色素夾雑物」とは、タンパク質の分解工程や、ペプチドの高温高圧処理工程において生じる有色副産物などをいい、また、工程中で各種の原料から混入したものも含まれる。本発明において低減される色素夾雑物は特に限定されるものではないが、特に褐色色素成分、タンパク質と糖分が反応したメイラード化合物群などが好適に低減される。
2-4. Reduction of pigment contaminants In one embodiment of the present invention, not only purines but also pigment contaminants can be selectively reduced. In the present specification, the “pigment contaminant” refers to a colored by-product generated in a protein decomposition step or a high-temperature high-pressure treatment step of a peptide, and includes those mixed from various raw materials in the step. The pigment contaminants to be reduced in the present invention are not particularly limited, but particularly brown pigment components, Maillard compound groups in which protein and sugar are reacted, and the like are suitably reduced.
３．ジケトピペラジン含有液を回収する回収工程
本発明では、接触工程の後、陽イオン交換樹脂からジケトピペラジン液状組成物を回収することで、液状組成物中のジケトピペラジン含有量の低下は抑えられる一方、液状組成物中のプリン体の含有量が低減されたジケトピペラジン含有液状組成物を得ることができる。接触工程後に、陽イオン交換樹脂から液状組成物を回収する態様は特に限定されるものではない。例えば、液状組成物と陽イオン交換樹脂との混合溶液を遠心分離又は濾過することにより、陽イオン交換樹脂から液状組成物を回収することができる。遠心分離の条件は特に限定されないが、例えば回転数は500〜10000rpm、好ましくは1000〜8000rpm、より好ましくは2000〜5000rpm、さらにより好ましくは3000〜4000rpmであり、遠心分離温度は1〜50℃、好ましくは10〜30℃、より好ましくは20〜25℃、さらにより好ましくは室温であり、遠心分離時間は1〜60分、好ましくは5〜30分、より好ましくは10〜20分である。また、陽イオン交換樹脂を充填したカラムにジケトピペラジン及びプリン体を含有する液状組成物を添加することで、液状組成物と陽イオン交換樹脂とを接触させた場合には、カラムからの漏出液中のジケトピペラジン含有画分を回収することで、ジケトピペラジン含有液状組成物を得ることができる。本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物では、プリン体はプリン塩基の状態で存在する。本発明は、液状組成物中のプリン塩基中の窒素原子の正電荷を利用し、プリン塩基を陽イオン交換樹脂に吸着させて分離するものである。とりわけ、本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物が、動植物由来原料又は動植物由来原料由来ペプチドから製造された高温高圧加工物等である場合、前記液状組成物中の核酸の構造を積極的に崩壊させていることから、確実にプリン体プリン体塩基の状態にして分離することが可能である。
3. Recovery step for recovering diketopiperazine-containing liquid In the present invention, after the contact step, the diketopiperazine liquid composition is recovered from the cation exchange resin, thereby suppressing the decrease in the diketopiperazine content in the liquid composition. On the other hand, a diketopiperazine-containing liquid composition in which the content of purines in the liquid composition is reduced can be obtained. The aspect in which the liquid composition is recovered from the cation exchange resin after the contacting step is not particularly limited. For example, the liquid composition can be recovered from the cation exchange resin by centrifuging or filtering the mixed solution of the liquid composition and the cation exchange resin. Centrifugation conditions are not particularly limited. For example, the rotational speed is 500 to 10000 rpm, preferably 1000 to 8000 rpm, more preferably 2000 to 5000 rpm, even more preferably 3000 to 4000 rpm, and the centrifugation temperature is 1 to 50 ° C., Preferably it is 10-30 degreeC, More preferably, it is 20-25 degreeC, More preferably, it is room temperature, Centrifugation time is 1-60 minutes, Preferably it is 5-30 minutes, More preferably, it is 10-20 minutes. In addition, when a liquid composition containing diketopiperazine and purine is added to a column filled with a cation exchange resin, if the liquid composition and the cation exchange resin are brought into contact with each other, leakage from the column will occur. By collecting the diketopiperazine-containing fraction in the liquid, a diketopiperazine-containing liquid composition can be obtained. In the liquid composition containing the diketopiperazine and the purine used in the present invention, the purine is present in a purine base state. The present invention utilizes a positive charge of a nitrogen atom in a purine base in a liquid composition, and adsorbs the purine base on a cation exchange resin for separation. In particular, when the liquid composition containing diketopiperazine and purine used in the present invention is a high-temperature high-pressure processed product produced from an animal or plant-derived raw material or an animal or plant-derived raw material-derived peptide, etc., in the liquid composition Since the structure of the nucleic acid is actively disrupted, it can be reliably separated into a purine purine base.
３−１．ジケトピペラジン含有液状組成物
一般に、Ｂｒｉｘ値が高い液状組成物は、原料由来の様々な物質（例えば、苦味成分）が高濃度で含まれることを意味する。Ｂｒｉｘ値が高い液状組成物は、香味や舌触りなどへの影響から飲料等への添加に適さない。従って、飲料等への添加を考えた場合、Ｂｒｉｘ値は低い方が好ましい。本発明では、ジケトピペラジンの含有量を維持したまま、プリン体や色素夾雑物の含有量を低減させた液状組成物、即ち、液状組成物のＢｒｉｘ値に対するジケトピペラジン含有量が高い液状組成物を得ることができる。
3-1. Diketopiperazine-containing liquid composition In general, a liquid composition having a high Brix value means that various substances derived from raw materials (for example, bitter components) are contained in high concentrations. A liquid composition having a high Brix value is not suitable for addition to beverages and the like because of its influence on flavor and touch. Therefore, when the addition to a drink etc. is considered, the one where a Brix value is lower is preferable. In the present invention, a liquid composition in which the content of purines and pigment contaminants is reduced while maintaining the diketopiperazine content, that is, a liquid composition having a high diketopiperazine content relative to the Brix value of the liquid composition. You can get things.
本発明により得られる、プリン体や色素夾雑物の含有量を低減したジケトピペラジン含有液状組成物は、香味がよく、沈殿や濁り等もなく外観にも優れるので、特別な後処理を施さなくても、エキス、調味料、飲料等にそのまま利用することができる。また、本発明で得られるジケトピペラジン含有液状組成物は、ジケトピペラジンの含有量が高いにも関わらず、Ｂｒｉｘ値が相対的に低いため、飲食物（特に、飲料）への配合量が少なくてよく、飲食物の設計の自由度が増すという利点もある。特に、茶飲料、コーヒー飲料、大豆飲料、果汁飲料等の植物の抽出液又は搾汁液等を主成分として配合して得られる飲料や、フレーバードウォーター、ミネラル飲料、炭酸飲料、ビール飲料、アルコール飲料などの様々な飲料に、そのまま配合することができる。例えば、本発明で製造される、プリン体や色素夾雑物の含有量を低減したジケトピペラジン含有液状組成物を飲料に配合すると、ジケトピペラジンの総量が１μｇ／１００ｇ以上、好ましくは１０μｇ／１００ｇ以上、より好ましくは４０μｇ／１００ｇ以上、さらに好ましくは６０μｇ／１００ｇ以上となるような飲料で、かつ苦味を呈しない風味良好な飲料を得ることができる。 The diketopiperazine-containing liquid composition obtained by the present invention and having a reduced content of purines and pigment contaminants has a good flavor and is excellent in appearance without precipitation, turbidity, etc. However, it can be used as it is for extracts, seasonings, beverages and the like. Moreover, since the diketopiperazine-containing liquid composition obtained in the present invention has a relatively low Brix value in spite of the high diketopiperazine content, the blended amount in foods and drinks (especially beverages) is low. There is also an advantage that the degree of freedom in designing food and drink is increased. In particular, beverages obtained by blending plant extracts or juices such as tea beverages, coffee beverages, soybean beverages, fruit juice beverages, etc. as the main components, flavored water, mineral beverages, carbonated beverages, beer beverages, alcoholic beverages It can be blended as it is in various beverages. For example, when a diketopiperazine-containing liquid composition with reduced content of purines and pigment contaminants produced in the present invention is added to a beverage, the total amount of diketopiperazine is 1 μg / 100 g or more, preferably 10 μg / 100 g. As described above, it is possible to obtain a beverage having a good flavor that is 40 μg / 100 g or more, more preferably 60 μg / 100 g or more and that does not exhibit a bitter taste.
本発明により得られるジケトピペラジン含有液状組成物は、添加する飲食物の態様に合わせて、清澄化処理等を行うこともできる。この場合、油分がないこと、繊維質が存在すること等の理由から、清澄化処理を容易に行うことができるという利点もある。 The diketopiperazine-containing liquid composition obtained by the present invention can be subjected to a clarification treatment or the like according to the aspect of the food or drink to be added. In this case, there is also an advantage that the clarification treatment can be easily performed due to the absence of oil and the presence of fiber.
本発明においては、プリン体及び色素夾雑物の含有量は、ＨＰＬＣやガスクロマトグラフィー、質量分析等の公知の方法で測定することができる。一例として、プリン体含有量の測定は、特に限定されないが、BOJC 2012年度活動報告書 P11 「プリン体-HPLC-UV法によるビール、発泡酒、新ジャンルの総プリン体定量」（http://www.brewers.or.jp/bcoj/pdf/2012_report_Japanese.pdf）に記載の方法やK.Kanekoらの方法（Nucleosides, Nucleotides and Nucleic Acids, 2014, 33: 439-444）に準じて行う。 In the present invention, the contents of purines and pigment contaminants can be measured by known methods such as HPLC, gas chromatography, and mass spectrometry. For example, measurement of purine content is not particularly limited, but BOJC 2012 Activity Report P11 “Purine-HPLC-UV Method for Determination of Total Purine in Beer, Happoshu, and New Genre” (http: // Follow the method described in www.brewers.or.jp/bcoj/pdf/2012_report_English.pdf) and the method of K.Kaneko et al. (Nucleosides, Nucleotides and Nucleic Acids, 2014, 33: 439-444).
本発明の別の一態様は、一定範囲のｐＨ条件下でジケトピペラジン及びプリン体を含有する液状組成物と陽イオン交換樹脂とを一定範囲の容積比率で接触させ、その後ジケトピペラジン含有液を回収することで、色素夾雑物の含有量が低減された液状組成物を製造する方法でもある。 Another aspect of the present invention is that a liquid composition containing diketopiperazine and purine and a cation exchange resin are contacted at a volume ratio in a certain range under a certain range of pH conditions, and then a diketopiperazine-containing liquid It is also a method for producing a liquid composition in which the content of pigment contaminants is reduced by collecting
本発明は、さらに別の一態様として、プリン体及び色素夾雑物の含有量が低減された液状組成物を提供する。プリン体及び色素夾雑物の含有量が低減された液状組成物中に含まれるジケトピペラジンの総量に限定はないが、好ましくは、１μｇ／１００ｇ／Ｂｒｉｘ以上、より好ましくは１０μｇ／１００ｇ／Ｂｒｉｘ以上、さらにより好ましくは１００μｇ／１００ｇ／Ｂｒｉｘ以上、最も好ましくは１０００μｇ／１００ｇ／Ｂｒｉｘ以上である。 As another aspect, the present invention provides a liquid composition in which the contents of purines and pigment contaminants are reduced. There is no limitation on the total amount of diketopiperazine contained in the liquid composition in which the content of purines and pigment contaminants is reduced, but preferably 1 μg / 100 g / Brix or more, more preferably 10 μg / 100 g / Brix or more. Even more preferably, it is 100 μg / 100 g / Brix or more, most preferably 1000 μg / 100 g / Brix or more.
本発明で使用されるジケトピペラジン及びプリン体を含有する液状組成物中に含まれるジケトピペラジンの総量に限定はないが、好ましくは、１μｇ／１００ｇ／Ｂｒｉｘ以上、より好ましくは１０μｇ／１００ｇ／Ｂｒｉｘ以上、さらにより好ましくは１００μｇ／１００ｇ／Ｂｒｉｘ以上、最も好ましくは１０００μｇ／１００ｇ／Ｂｒｉｘ以上である。 The total amount of diketopiperazine contained in the liquid composition containing the diketopiperazine and purine used in the present invention is not limited, but preferably 1 μg / 100 g / Brix or more, more preferably 10 μg / 100 g / Brix or more, even more preferably 100 μg / 100 g / Brix or more, most preferably 1000 μg / 100 g / Brix or more.
本発明で提供される、プリン体及び色素夾雑物の含有量が低減された液状組成物中に含まれるプリン体の総量に対するジケトピペラジンの総量の比率（ジケトピペラジンの総量／プリン体の総量）に限定はないが、好ましくは３．５以上、より好ましくは４．０以上、さらにより好ましくは５．０以上である。 The ratio of the total amount of diketopiperazine to the total amount of purines contained in the liquid composition with reduced contents of purines and pigment contaminants provided by the present invention (total amount of diketopiperazine / total amount of purines) ) Is not limited, but is preferably 3.5 or more, more preferably 4.0 or more, and even more preferably 5.0 or more.
本発明の方法により製造された、プリン体及び色素夾雑物の含有量が低減された液状組成物は、香味がよく、沈殿や濁り等もなく外観にも優れるため、特別な後処理を施すことなく、エキス、調味料、飲料等の飲食品や加工品に好適に用いることができる。尚、その際の配合量は一概には決定されず、飲食品や加工品の種類に応じて適宜調整される。 The liquid composition produced by the method of the present invention and containing a reduced content of purines and pigment contaminants has a good flavor and is excellent in appearance without precipitation or turbidity, and therefore is subjected to a special post-treatment. And can be suitably used for foods and beverages such as extracts, seasonings, and beverages, and processed products. In addition, the compounding quantity in that case is not decided unconditionally, and is suitably adjusted according to the kind of food-drinks or processed goods.
４．飲食品の製造方法
本発明は一態様として、飲食品を製造する方法である。具体的には、ジケトピペラジン及びプリン体を含有する液状組成物と陽イオン交換樹脂とを接触させる工程、ジケトピペラジン含有液を回収する工程、及び、ジケトピペラジン含有液を回収して得られた液状組成物を飲食品に添加する工程を含み、接触工程において、陽イオン交換樹脂とジケトピペラジン及びプリン体を含有する液状組成物との容積比率（陽イオン交換樹脂の容積：ジケトピペラジン及びプリン体を含有する液状組成物の容積）が１：０．５〜１：１０であり、陽イオン交換樹脂に接触させるジケトピペラジン及びプリン体を含有する液状組成物のｐＨが２．０〜６．０である、飲食品を製造する方法である。製造される飲食品は特に限定されないが、例えば、インスタント食品、健康食品、サプリメントなどが挙げられる。
4). The manufacturing method of food-drinks This invention is the method of manufacturing food-drinks as one aspect | mode. Specifically, a step of bringing a liquid composition containing a diketopiperazine and purine into contact with a cation exchange resin, a step of recovering a diketopiperazine-containing liquid, and a step of recovering the diketopiperazine-containing liquid A volume ratio of the cation exchange resin to the liquid composition containing the diketopiperazine and the purine body (volume of the cation exchange resin: diketo). The volume of the liquid composition containing piperazine and purine bodies is 1: 0.5 to 1:10, and the pH of the liquid composition containing diketopiperazine and purine bodies to be contacted with the cation exchange resin is 2. It is the method of manufacturing food-drinks which are 0-6.0. Although the food-drinks manufactured are not specifically limited, For example, an instant food, health food, a supplement, etc. are mentioned.
本発明における飲食品の製造方法は、本明細書の記載及び当業者に知られる通常の方法に基づいて行うことができる。例えば、健康食品の製造方法においては、プリン体及び色素夾雑物の含有量が低減された液状組成物を配合し、さらに必要に応じて希釈剤、担体、結合剤、崩壊剤、滑沢剤、矯味矯臭剤、溶解補助剤、懸濁剤、コーティング剤等の健康食品分野において通常使用する公知の添加剤及び／又は補助剤を添加することができる。剤型としては、錠剤、カプセル剤、ソフトカプセル剤等を挙げることができ、特に限定されるものではない。 The manufacturing method of the food / beverage products in this invention can be performed based on the description of this specification, and the normal method known to those skilled in the art. For example, in the method for producing health food, a liquid composition with reduced contents of purines and pigment contaminants is blended, and further a diluent, carrier, binder, disintegrant, lubricant, Known additives and / or adjuvants commonly used in the field of health food such as flavoring agents, solubilizing agents, suspending agents, and coating agents can be added. Examples of the dosage form include tablets, capsules, soft capsules and the like, and are not particularly limited.
本発明の一態様として、ビール等の麦芽使用飲料を製造する方法が挙げられる。麦芽使用飲料としては、ビール、発泡酒などのアルコール飲料、ノンアルコール飲料が挙げられるが、これに限定されるものではない。 As one aspect of the present invention, a method for producing a malt beverage such as beer can be mentioned. Examples of the malt beverage include alcoholic beverages such as beer and sparkling liquor, and non-alcoholic beverages, but are not limited thereto.
本発明における麦芽使用のアルコール飲料の製造方法は、当業者に知られる通常の方法を好適に追加して行うことができる。例えば、炭素源と、必要に応じて、追加の窒素源と、苦味料、又は着色料などの原料を、仕込釜又は仕込槽に投入し、必要に応じてアミラーゼなどの酵素を添加し、糊化、糖化を行なわせ、濾過し、必要に応じてホップなどを加えて煮沸し、清澄タンクにて凝固タンパクなどの固形分を取り除いて麦汁とする。糖化工程、煮沸工程、固形分除去工程などにおける条件は、知られている条件を用いればよい。次いで酵母を添加して発酵を行なわせ、濾過機などで酵母を取り除いて製造することができる。酵母は、発酵後に取り除かずに飲料中に残すこともできる。発酵条件は、知られている条件を用いればよい。更に、貯酒、必要により炭酸添加、濾過、殺菌の工程を経て、麦芽使用飲料を得ることができる。また、本発明における麦芽使用のノンアルコール飲料の製造方法も、当業者に知られる通常の方法を好適に追加して行うことができる。例えば、アルコール飲料における麦汁のエキス分量を調整し、甘味料、香料、酵母エキス、カラメル色素等の着色料、コーンや大豆などの植物タンパク質及びペプチド含有物等のタンパク質系物質、食物繊維やアミノ酸などの調味料、アスコルビン酸等の酸化防止剤、各種酸味料を、本発明の効果を妨げない範囲で必要に応じて添加し、貯蔵、炭酸ガス添加、濾過、容器詰め、必要により殺菌の工程を経て、麦芽使用のノンアルコール飲料を得ることができる。 The method for producing an alcoholic beverage using malt in the present invention can be performed by suitably adding a normal method known to those skilled in the art. For example, a carbon source, and if necessary, an additional nitrogen source and a raw material such as a bittering agent or a coloring agent are charged into a charging vessel or a charging tank, and an enzyme such as amylase is added as necessary. And saccharify, filter, add hops if necessary, boil, remove solids such as coagulated protein in a clarification tank, and make wort. Known conditions may be used as conditions in the saccharification process, boiling process, solid content removal process, and the like. Next, yeast can be added to perform fermentation, and the yeast can be removed by using a filter or the like. The yeast can also be left in the beverage without being removed after fermentation. What is necessary is just to use known conditions for fermentation conditions. Furthermore, a malt-use beverage can be obtained through the steps of storing alcohol, and if necessary, adding carbonic acid, filtering, and sterilizing. Moreover, the manufacturing method of the non-alcohol drink using the malt in this invention can also be performed suitably adding the normal method known to those skilled in the art. For example, adjusting the amount of wort extract in alcoholic beverages, sweeteners, flavorings, yeast extracts, colorants such as caramel pigments, protein-based substances such as plant proteins and peptide products such as corn and soybeans, dietary fibers and amino acids Seasoning such as ascorbic acid, antioxidants such as ascorbic acid, various acidulants are added as necessary within the range that does not interfere with the effect of the present invention, storage, carbon dioxide addition, filtration, container packing, if necessary sterilization process Through the process, a non-alcoholic beverage using malt can be obtained.
本発明の方法にあるジケトピペラジン及びプリン体を含有する液状組成物を陽イオンに接触させる工程は、上記製造工程のいずれの段階で行ってもよい。例えば、あらかじめジケトピペラジン及びプリン体を含有する液状組成物を麦汁（ホップを含んでもよい。）に混合したものを陽イオン交換樹脂に接触させてもよい。あるいは、水に浸漬した麦芽（副原料を含んでもよい）にジケトピペラジン及びプリン体を含有する液状組成物及び／又は動植物由来原料（麦芽エキスなど）を加えた混合物を高温高圧処理して得られる糖化もろみから麦汁を製造し、これを陽イオン交換樹脂に接触させてもよい。あるいはまた、あらかじめジケトピペラジン及びプリン体を含有する液状組成物を陽イオン交換樹脂に接触させ回収したジケトピペラジン含有組成物を、麦汁に混合し、その後の工程に用いることもできる。 The step of bringing the liquid composition containing the diketopiperazine and the purine body into contact with the cation in the method of the present invention may be performed at any stage of the above production process. For example, a liquid composition containing diketopiperazine and purine in advance mixed with wort (may contain hops) may be brought into contact with the cation exchange resin. Alternatively, a mixture obtained by adding a liquid composition containing diketopiperazine and purine bodies and / or animal and plant-derived materials (malt extract etc.) to malt (which may contain auxiliary materials) immersed in water is obtained by high-temperature and high-pressure treatment. Wort may be produced from the resulting saccharified moromi and then contacted with a cation exchange resin. Alternatively, a diketopiperazine-containing composition recovered by bringing a liquid composition containing diketopiperazine and purine into contact with a cation exchange resin in advance can be mixed with wort and used in subsequent steps.
本発明のビール飲料は、容器詰めとすることができる。容器の形態は何ら制限されず、ビン、缶、樽、またはペットボトル等の密封容器に充填して、容器入り飲料とすることができる。 The beer beverage of the present invention can be packed in a container. The form of the container is not limited at all, and can be filled into a sealed container such as a bottle, a can, a barrel, or a plastic bottle to make a beverage with a container.
本発明では、飲食品に通常配合する添加剤、例えば、香料、ビタミン類、色素類、酸化防止剤、乳化剤、保存料、調味料、エキス類、ｐＨ調整剤、糖類、酸味料、品質安定剤等を添加する工程を含むこともできる。 In the present invention, additives usually blended in foods and drinks, such as fragrances, vitamins, pigments, antioxidants, emulsifiers, preservatives, seasonings, extracts, pH adjusters, sugars, acidulants, quality stabilizers The process of adding etc. can also be included.
５．プリン体及び色素夾雑物の含有量低減方法
本発明の一態様は、液状組成物に含まれるプリン体及び色素夾雑物の含有量を低減する方法である。具体的には、一定範囲のｐＨ条件下でジケトピペラジン及びプリン体を含有する液状組成物と陽イオン交換樹脂とを一定範囲の比率で接触させ、その後ジケトピペラジンを回収することで、液状組成物中のプリン体及び色素夾雑物の含有量を低減する方法である。ジケトピペラジン及びプリン体を含有する液状組成物及びその他の条件は前記方法と同様である。
5. Method for reducing contents of purine bodies and pigment contaminants One embodiment of the present invention is a method for reducing the contents of purine bodies and pigment contaminants contained in a liquid composition. Specifically, a liquid composition containing a diketopiperazine and purine body and a cation exchange resin are contacted at a ratio in a certain range under a certain range of pH conditions, and then the diketopiperazine is recovered to obtain a liquid. This is a method for reducing the content of purines and pigment contaminants in the composition. The liquid composition containing diketopiperazine and purine and other conditions are the same as in the above method.
以下、実施例に基づいて本発明を説明するが、本発明はこれらの実施例に限定されるものではない。また、本明細書において特記しない限り、濃度等は重量基準であり、数値範囲はその端点を含むものとして記載される。 EXAMPLES Hereinafter, although this invention is demonstrated based on an Example, this invention is not limited to these Examples. Further, unless otherwise specified in the present specification, the concentration and the like are based on weight, and the numerical range is described as including the end points.
（実験材料）
１．イオン交換樹脂
Column PD-10, Empty（GE Healthcare製）にイオン交換樹脂5ccを移した後、蒸留水50mLで洗浄し、使用まで4℃で保管した。陽イオン交換樹脂には、アンバーライトIR 120B H AG（オルガノ社）、アンバーライトIR 124H H AG（オルガノ社）、アンバーライト200CT H AG（オルガノ社）、アンバーライト252NA（オルガノ社）、アンバーライトIRC76 AG（オルガノ社）、及びアンバーライトFPC3500（オルガノ社）を用いた。陰イオン交換樹脂にはアンバーライトXE583（オルガノ社）及びアンバーライトIRA400 OH AG（オルガノ社）を用いた。
(Experimental material)
1. Ion exchange resin
After transferring 5 cc of ion exchange resin to Column PD-10, Empty (manufactured by GE Healthcare), it was washed with 50 mL of distilled water and stored at 4 ° C. until use. Cation exchange resins include Amberlite IR 120B H AG (organo), Amberlite IR 124H H AG (organo), Amberlite 200CT H AG (organo), Amberlite 252NA (organo), Amberlite IRC76 AG (organo) and Amberlite FPC3500 (organo) were used. Amberlite XE583 (organo) and Amberlite IRA400 OH AG (organo) were used as the anion exchange resin.
２．活性炭
Column PD-10, Empty（GE Healthcare製）に活性炭5ccを移した後、蒸留水10mLで洗浄した。次いで、5％NaOH 10mLで洗浄し、熱水10mLで洗浄し、1％HCl 10mLで洗浄し、蒸留水25mLで洗浄し、洗浄液が中性であることを確認し、使用まで4℃で保管した。活性炭には、ホクエツCL-K（味の素ファインテクノ社）を用いた。
2. Activated carbon
After moving 5 cc of activated carbon to Column PD-10, Empty (manufactured by GE Healthcare), it was washed with 10 mL of distilled water. It was then washed with 10 mL of 5% NaOH, washed with 10 mL of hot water, washed with 10 mL of 1% HCl, washed with 25 mL of distilled water, confirmed to be neutral, and stored at 4 ° C. until use. . As the activated carbon, Hokuetsu CL-K (Ajinomoto Fine Techno Co., Ltd.) was used.
３．大豆エキス由来液状組成物（大豆液状組成物）の調製
ハイニュートAMを200mg/mLになるように蒸留水に溶解し、132℃で3時間高温高圧処理し、大豆液状組成物を調製した。pHを酸性に調整する場合（pH3.5, pH3.0, pH2.5）はリン酸（食品添加物：和光純薬工業製）を添加してpHを調整し、生じた沈殿を、3500rpm、室温、10分間遠心し、得られた上清を実験に用いた。
3. Preparation of soybean extract-derived liquid composition (soybean liquid composition) High Newt AM was dissolved in distilled water to 200 mg / mL and subjected to high-temperature and high-pressure treatment at 132 ° C for 3 hours to prepare a soybean liquid composition. When adjusting the pH to acidic (pH 3.5, pH 3.0, pH 2.5), the pH is adjusted by adding phosphoric acid (food additive: Wako Pure Chemical Industries, Ltd.), and the resulting precipitate is 3500 rpm, After centrifugation at room temperature for 10 minutes, the resulting supernatant was used for the experiment.
実施例１：樹脂処理による大豆液状組成物からのプリン体の低減効果
１．樹脂処理による大豆液状組成物中のプリン体の低減
大豆液状組成物をpH3.5に調整した溶液25mLを50mLのファルコンチューブに分注した。その後、前処理した樹脂5ccを添加し、10分毎にチューブを転倒混和し、60分間バッチ法で、大豆液状組成物を樹脂に接触させた。60分経過後、チューブを3500rpm、室温、10分間遠心し、得られた上清を、精製大豆エキス由来液状組成物（精製大豆液状組成物）とした。また、大豆液状組成物及び精製大豆液状組成物のBrix値は、デジタル屈折計RX-5000α（ATAGO）を用いて測定した。
Example 1: Reduction effect of purines from soybean liquid composition by resin treatment
1. Reduction of purines in soybean liquid composition by resin treatment 25 mL of a solution in which soybean liquid composition was adjusted to pH 3.5 was dispensed into a 50 mL falcon tube. Thereafter, 5 cc of pretreated resin was added, the tube was mixed by inversion every 10 minutes, and the soybean liquid composition was brought into contact with the resin by a batch method for 60 minutes. After 60 minutes, the tube was centrifuged at 3500 rpm and room temperature for 10 minutes, and the resulting supernatant was used as a purified soybean extract-derived liquid composition (purified soybean liquid composition). The Brix value of the soybean liquid composition and the purified soybean liquid composition was measured using a digital refractometer RX-5000α (ATAGO).
２．大豆液状組成物及び精製大豆液状組成物中のTyr-DKPsの定量
（１）大豆液状組成物及び精製大豆液状組成物の固相抽出
大豆液状組成物又は精製大豆液状組成物を、Brix値が1となるように蒸留水で希釈したものを10mL調製した。大豆液状組成物又は精製大豆液状組成物を固相カートリッジに添加する前に、固相カートリッジOASIS HLB Plus（waters製）のコンディショニングを行なった。即ち、OASIS HLB Plusにアセトニトリル5mLを添加し、次いで蒸留水5mLを添加した。
2. Determination of Tyr-DKPs in Soybean Liquid Composition and Refined Soybean Liquid Composition (1) Solid Phase Extraction of Soybean Liquid Composition and Purified Soybean Liquid Composition 10 mL of a solution diluted with distilled water was prepared so that Before adding the soybean liquid composition or the purified soybean liquid composition to the solid phase cartridge, the solid phase cartridge OASIS HLB Plus (manufactured by waters) was conditioned. That is, 5 mL of acetonitrile was added to OASIS HLB Plus, and then 5 mL of distilled water was added.
コンディショニング後の固相カートリッジOASIS HLB Plusに対し、Brix値を1に調製した大豆液状組成物又は精製大豆液状組成物を10mL添加し、次いで蒸留水5mLを添加した。その後、アセトニトリル3mLを添加し、溶出物を試験管に移し減圧濃縮した。その後減圧濃縮試料をジメチルスルホキシド1mLで溶解し、HPLC用試料とした。 To the OASIS HLB Plus after conditioning, 10 mL of a soybean liquid composition or a purified soybean liquid composition prepared with a Brix value of 1 was added, and then 5 mL of distilled water was added. Thereafter, 3 mL of acetonitrile was added, and the eluate was transferred to a test tube and concentrated under reduced pressure. Thereafter, the vacuum concentrated sample was dissolved in 1 mL of dimethyl sulfoxide to obtain a sample for HPLC.
（２）Tyr-DKPsの定量
HPLC：LC-2010 CHT（SHIMADZU製）
カラム：Devolesil C30 UG-5 (4.6mm x 150mm)（野村化学製）
移動相：バッファーA：0.1％ギ酸を含んだ蒸留水
バッファーB：0.1％ギ酸を含んだ80%アセトニトリル蒸留水
グラジエントプログラム：
5%バッファーB/95%バッファーA →20%バッファーB/80%バッファーA
（リニアグラジエント：60分）
流速：1mL/min
検出波長：215nm
サンプル量：10μL/injection
標準品：Cyclo(Ser-Tyr), Cyclo(Asn-Tyr), Cyclo(Tyr-Gly), Cyclo(Tyr-Tyr),
Cyclo(Leu-Tyr), Cyclo(Val-Tyr), Cyclo(Ile-Tyr), Cyclo(Phe-Tyr)
上記条件で、HPLC用試料中のTyr-DKPsを測定し、大豆液状組成物及び精製大豆液状組成物中のTyr-DKPs量を求めた。結果を図１に示す。
(2) Quantification of Tyr-DKPs
HPLC: LC-2010 CHT (manufactured by SHIMADZU)
Column: Devolesil C30 UG-5 (4.6mm x 150mm) (Nomura Chemical)
Mobile phase: Buffer A: Distilled water containing 0.1% formic acid
Buffer B: 80% acetonitrile distilled water containing 0.1% formic acid Gradient program:
5% buffer B / 95% buffer A → 20% buffer B / 80% buffer A
(Linear gradient: 60 minutes)
Flow rate: 1mL / min
Detection wavelength: 215nm
Sample volume: 10μL / injection
Standard products: Cyclo (Ser-Tyr), Cyclo (Asn-Tyr), Cyclo (Tyr-Gly), Cyclo (Tyr-Tyr),
Cyclo (Leu-Tyr), Cyclo (Val-Tyr), Cyclo (Ile-Tyr), Cyclo (Phe-Tyr)
Under the above conditions, Tyr-DKPs in the HPLC sample was measured, and the amount of Tyr-DKPs in the soybean liquid composition and the purified soybean liquid composition was determined. The results are shown in FIG.
３．大豆液状組成物及び精製大豆液状組成物中のプリン体量の定量
（１）大豆液状組成物及び精製大豆液状組成物の過塩素酸分解
大豆液状組成物又は精製大豆液状組成物4.5mLを蓋付き試験管にとり、70％過塩素酸0.5mLと混合し、ブロックヒーターを用いて95℃、60分間加熱して、加水分解させた。次いで、試験管を氷中に移し、8M 水酸化カリウム水溶液1mLを加え混合し、中和した。中和物を遠心チューブに移し、3500rpm、室温、10分間遠心し、得られた上清を、HPLC用試料とした。
3. Determination of purine content in soybean liquid composition and purified soybean liquid composition (1) Perchloric acid decomposition of soybean liquid composition and purified soybean liquid composition 4.5 ml of soybean liquid composition or purified soybean liquid composition is covered The sample was taken in a test tube, mixed with 0.5 mL of 70% perchloric acid, and hydrolyzed by heating at 95 ° C. for 60 minutes using a block heater. Next, the test tube was transferred to ice, and 1 mL of 8M aqueous potassium hydroxide solution was added and mixed to neutralize. The neutralized product was transferred to a centrifuge tube, centrifuged at 3500 rpm, room temperature for 10 minutes, and the resulting supernatant was used as a sample for HPLC.
（２）プリン体量のHPLC法での定量
HPLC：LC-2010 CHT（SHIMADZU製）
カラム：Shodex Asahi GS-320 HQ (7.5mm x 300mm)（昭和電工製）
移動相：150mM リン酸ナトリウムバッファー（pH2.5）
グラジエントプログラム：アイソクラティック
流速：0.5mL/min
検出波長：260nm
サンプル量：10μL/injection
標準品：アデニン、グアニン、ヒポキサンチン、キサンチン
上記条件で、HPLC用試料中のプリン体を測定し、大豆液状組成物及び精製大豆液状組成物中のプリン体量を求めた。結果を図２に示す。
(2) Determination of purine content by HPLC method
HPLC: LC-2010 CHT (manufactured by SHIMADZU)
Column: Shodex Asahi GS-320 HQ (7.5mm x 300mm) (made by Showa Denko)
Mobile phase: 150 mM sodium phosphate buffer (pH 2.5)
Gradient program: Isocratic Flow rate: 0.5mL / min
Detection wavelength: 260nm
Sample volume: 10μL / injection
Standard products: adenine, guanine, hypoxanthine, xanthine Purine bodies in the sample for HPLC were measured under the above conditions, and the amounts of purine bodies in the soybean liquid composition and the purified soybean liquid composition were determined. The results are shown in FIG.
大豆液状組成物を、陽イオン交換樹脂と接触させた結果、単位BrixあたりのTyr-DKPs量は未処理群と同程度もしくはそれ以上に濃縮されるが、単位Brixあたりのプリン体量は未処理群と比べて減少することが示された。一方で、陰イオン交換樹脂や活性炭と接触させた場合、単位Brixあたりのプリン体量と共に、単位BrixあたりのTyr-DKPs量も未処理群と比べて減少することが示された。 As a result of contacting the soybean liquid composition with the cation exchange resin, the amount of Tyr-DKPs per unit Brix is concentrated to the same level or higher than that of the untreated group, but the amount of purine per unit Brix is untreated. It was shown to decrease compared to the group. On the other hand, when contacting with an anion exchange resin or activated carbon, it was shown that the amount of Tyr-DKPs per unit Brix was reduced as well as the amount of purine per unit Brix compared to the untreated group.
実施例２：樹脂処理による大豆液状組成物からのプリン体の低減効果に及ぼすpHの影響
１．樹脂処理による大豆液状組成物からのプリン体の低減
大豆液状組成物をpH2.5, pH3.0, pH3.5, pH未調整(pH5.8)に調整した溶液25mLを50mLのファルコンチューブに分注した。その後、前処理した樹脂5ccを添加し、10分毎にチューブを転倒混和し、60分間バッチ法で、大豆液状組成物を樹脂に接触させた。60分経過後、チューブを3500rpm、室温、10分間遠心し、得られた上清を、精製大豆液状組成物とした。大豆液状組成物及び精製大豆液状組成物のBrix値は、デジタル屈折計RX-5000α（ATAGO）を用いて測定した。
Example 2: Effect of pH on the reduction effect of purines from soybean liquid composition by resin treatment
1. Reduction of purines from soybean liquid composition by resin treatment Divide 25 mL solution of soybean liquid composition to pH 2.5, pH 3.0, pH 3.5, pH unadjusted (pH 5.8) into 50 mL Falcon tube Noted. Thereafter, 5 cc of pretreated resin was added, the tube was mixed by inversion every 10 minutes, and the soybean liquid composition was brought into contact with the resin by a batch method for 60 minutes. After 60 minutes, the tube was centrifuged at 3500 rpm, room temperature for 10 minutes, and the resulting supernatant was used as a purified soybean liquid composition. The Brix value of the soybean liquid composition and the purified soybean liquid composition was measured using a digital refractometer RX-5000α (ATAGO).
２．大豆液状組成物及び精製大豆液状組成物中のTyr-DKPsの定量
（１）大豆液状組成物及び精製大豆液状組成物の固相抽出
大豆液状組成物及び精製大豆液状組成物を、Brix値が1になるように蒸留水で希釈したものを10mL調製した。大豆液状組成物及び精製大豆液状組成物を固相カートリッジに添加する前に、固相カートリッジOASIS HLB Plus（waters製）のコンディショニングを行なった。即ち、OASIS HLB Plusにアセトニトリル5mLを添加し、次いで蒸留水5mLを添加した。
2. Determination of Tyr-DKPs in Soybean Liquid Composition and Purified Soybean Liquid Composition (1) Solid Phase Extraction of Soybean Liquid Composition and Purified Soybean Liquid Composition Soybean Liquid Composition and Purified Soybean Liquid Composition with Brix Value of 1 10 mL of the product diluted with distilled water was prepared. Before adding the soybean liquid composition and the purified soybean liquid composition to the solid phase cartridge, the solid phase cartridge OASIS HLB Plus (manufactured by waters) was conditioned. That is, 5 mL of acetonitrile was added to OASIS HLB Plus, and then 5 mL of distilled water was added.
コンディショニング後の固相カートリッジOASIS HLB Plusに対し、Brix値を1に調製した大豆液状組成物又は精製大豆液状組成物を10mL添加し、次いで蒸留水5mLを添加した。その後、アセトニトリル3mLを添加し、溶出物を試験管に移し減圧濃縮した。その後減圧濃縮試料をジメチルスルホキシド1mLで溶解し、HPLC用試料とした。 To the OASIS HLB Plus after conditioning, 10 mL of a soybean liquid composition or a purified soybean liquid composition prepared with a Brix value of 1 was added, and then 5 mL of distilled water was added. Thereafter, 3 mL of acetonitrile was added, and the eluate was transferred to a test tube and concentrated under reduced pressure. Thereafter, the vacuum concentrated sample was dissolved in 1 mL of dimethyl sulfoxide to obtain a sample for HPLC.
（２）Tyr-DKPsの定量
HPLC：LC-2010 CHT（SHIMADZU製）
カラム：Devolesil C30 UG-5 (4.6mm x 150mm)（野村化学製）
移動相：バッファーA：0.1％ギ酸を含んだ蒸留水、
バッファーB：0.1％ギ酸を含んだ80%アセトニトリル蒸留水
グラジエントプログラム：
5%バッファーB/95%バッファーA →20%バッファーB/80%バッファーA
（リニアグラジエント：60分）
流速：1mL/min
検出波長：215nm
サンプル量：10μL/injection
標準品：cyclo (Ser-Tyr), cyclo (Asn-Tyr), cyclo (Tyr-Gly), cyclo (Tyr-Tyr),
cyclo (Leu-Tyr), cyclo (Val-Tyr), cyclo (Ile-Tyr), cyclo (Phe-Tyr)
上記条件で、HPLC用試料中のTyr-DKPsを測定し、大豆液状組成物及び精製大豆液状組成物中のTyr-DKPs量を求めた。結果を図３〜６に示す。
(2) Quantification of Tyr-DKPs
HPLC: LC-2010 CHT (manufactured by SHIMADZU)
Column: Devolesil C30 UG-5 (4.6mm x 150mm) (Nomura Chemical)
Mobile phase: Buffer A: distilled water containing 0.1% formic acid,
Buffer B: 80% acetonitrile distilled water containing 0.1% formic acid Gradient program:
5% buffer B / 95% buffer A → 20% buffer B / 80% buffer A
(Linear gradient: 60 minutes)
Flow rate: 1mL / min
Detection wavelength: 215nm
Sample volume: 10μL / injection
Standard products: cyclo (Ser-Tyr), cyclo (Asn-Tyr), cyclo (Tyr-Gly), cyclo (Tyr-Tyr),
cyclo (Leu-Tyr), cyclo (Val-Tyr), cyclo (Ile-Tyr), cyclo (Phe-Tyr)
Under the above conditions, Tyr-DKPs in the HPLC sample was measured, and the amount of Tyr-DKPs in the soybean liquid composition and the purified soybean liquid composition was determined. The results are shown in FIGS.
３．大豆液状組成物及び精製大豆液状組成物中のプリン体量のHPLC法での定量
（１）大豆液状組成物及び精製大豆液状組成物の過塩素酸分解
大豆液状組成物又は精製大豆液状組成物4.5mLを蓋付き試験管にとり、70％過塩素酸 0.5mlと混合させ、ブロックヒーターを用いて95℃、60分間加熱して、加水分解させた。次いで、試験管を氷中に移し、8M 水酸化カリウム水溶液1mLを加え混合し、中和した。中和物を遠心チューブに移し、3500rpm、室温、10分間遠心し、得られた上清を、HPLC用試料とした。
3. Determination of Purine Amount in Soybean Liquid Composition and Purified Soybean Liquid Composition by HPLC Method (1) Perchloric Acid Decomposition of Soybean Liquid Composition and Purified Soybean Liquid Composition Soybean Liquid Composition or Purified Soybean Liquid Composition 4.5 mL was taken into a test tube with a lid, mixed with 0.5 ml of 70% perchloric acid, and hydrolyzed by heating at 95 ° C. for 60 minutes using a block heater. Next, the test tube was transferred to ice, and 1 mL of 8M aqueous potassium hydroxide solution was added and mixed to neutralize. The neutralized product was transferred to a centrifuge tube, centrifuged at 3500 rpm, room temperature for 10 minutes, and the resulting supernatant was used as a sample for HPLC.
（２）プリン体のHPLC法での定量
HPLC：LC-2010 CHT（SHIMADZU製）
カラム：Shodex Asahi GS-320 HQ (7.5mm x 300mm)（昭和電工製）
移動相：150mM リン酸ナトリウムバッファー（pH2.5）
グラジエントプログラム：アイソクラティック
流速：0.5mL/min
検出波長：260nm
サンプル量：10μL/injection
標準品：アデニン、グアニン、ヒポキサンチン、キサンチン
上記条件で、HPLC用試料中のプリン体を測定し、大豆液状組成物及び精製大豆液状組成物中のプリン体量を求めた。結果を図７〜１０に示す。
(2) Determination of purines by HPLC
HPLC: LC-2010 CHT (manufactured by SHIMADZU)
Column: Shodex Asahi GS-320 HQ (7.5mm x 300mm) (made by Showa Denko)
Mobile phase: 150 mM sodium phosphate buffer (pH 2.5)
Gradient program: Isocratic Flow rate: 0.5mL / min
Detection wavelength: 260nm
Sample volume: 10μL / injection
Standard products: adenine, guanine, hypoxanthine, xanthine Purine bodies in the sample for HPLC were measured under the above conditions, and the amounts of purine bodies in the soybean liquid composition and the purified soybean liquid composition were determined. The results are shown in FIGS.
図３〜１０の結果から、大豆液状組成物のpHを2.5, 3.0, 3.5, 及び5.8に調整して陽イオン交換樹脂と接触させた場合、陰イオン交換樹脂や活性炭と接触させた場合に比べて単位BrixあたりのTyr-DKPs量の減少が抑えられた。一方で、単位Brixあたりのプリン体量は未処理群と比べて減少することが示された。また、陽イオン交換樹脂と接触させる大豆液状組成物のpHがpH3.5又はpH5.8の場合、pH2.5又は3.0である場合と比較して、未処理群に対する単位BrixあたりのTyr-DKPs量の低下の程度が小さい傾向にあることが示唆された。 From the results of FIGS. 3 to 10, when the pH of the soybean liquid composition is adjusted to 2.5, 3.0, 3.5, and 5.8 and brought into contact with the cation exchange resin, compared with the case of bringing into contact with the anion exchange resin or activated carbon. Therefore, the decrease in the amount of Tyr-DKPs per unit Brix was suppressed. On the other hand, it was shown that the amount of purine bodies per unit Brix decreased compared to the untreated group. In addition, when the pH of the soybean liquid composition to be contacted with the cation exchange resin is pH 3.5 or pH 5.8, Tyr-DKPs per unit Brix relative to the untreated group compared to the case of pH 2.5 or 3.0 It was suggested that the degree of decrease in the amount tends to be small.
尚、活性炭を用いた場合には、pHにかかわらず、単位Brixあたりのプリン体量と単位BrixあたりのTyr-DKPs量共に未処理群と比べて大きく減少していた。 When activated carbon was used, both the amount of purine per unit Brix and the amount of Tyr-DKPs per unit Brix were greatly reduced compared to the untreated group regardless of pH.
実施例３：樹脂処理による大豆液状組成物からのプリン体の低減効果に及ぼす樹脂：大豆液状組成物比の影響
１．樹脂処理による大豆液状組成物からのプリン体の低減
（樹脂：大豆液状組成物＝1：5）
大豆液状組成物をpH3.5に調整した溶液25mLを50mLのファルコンチューブに分注した。その後、前処理した樹脂5ccを添加し、10分毎にチューブを転倒混和し、60分間バッチ法で、大豆液状組成物を樹脂と接触させた。
Example 3: Effect of resin: soybean liquid composition ratio on reduction effect of purines from soybean liquid composition by resin treatment
1. Reduction of purines from soybean liquid composition by resin treatment (resin: soybean liquid composition = 1: 5)
25 mL of a solution prepared by adjusting the soybean liquid composition to pH 3.5 was dispensed into a 50 mL Falcon tube. Thereafter, 5 cc of pretreated resin was added, the tube was mixed by inversion every 10 minutes, and the soybean liquid composition was brought into contact with the resin by a batch method for 60 minutes.
（樹脂：大豆液状組成物＝1：2又は1：1）
大豆液状組成物をpH3.5に調整した溶液10mLを50mLのファルコンチューブに分注した。その後、前処理した樹脂5cc（1：2）又は10cc（1：1）を添加し、10分毎にチューブを転倒混和し、60分間バッチ法で、大豆液状組成物を樹脂と接触させた。
(Resin: Soybean liquid composition = 1: 2 or 1: 1)
10 mL of a solution prepared by adjusting the soy liquid composition to pH 3.5 was dispensed into a 50 mL Falcon tube. Thereafter, 5 cc (1: 2) or 10 cc (1: 1) of the pretreated resin was added, the tube was mixed by inversion every 10 minutes, and the soybean liquid composition was brought into contact with the resin by a batch method for 60 minutes.
尚、60分経過後、チューブを3500rpm、室温、10分間遠心し、得られた上清を、精製大豆液状組成物とした。大豆液状組成物及び精製大豆液状組成物のBrix値は、デジタル屈折計RX-5000α（ATAGO）を用いて測定した。 After 60 minutes, the tube was centrifuged at 3500 rpm, room temperature for 10 minutes, and the resulting supernatant was used as a purified soybean liquid composition. The Brix value of the soybean liquid composition and the purified soybean liquid composition was measured using a digital refractometer RX-5000α (ATAGO).
２．大豆液状組成物及び精製大豆液状組成物中のTyr-DKPsの定量
（１）大豆液状組成物及び精製大豆液状組成物の固相抽出
大豆液状組成物又は精製大豆液状組成物を、Brix値が1になるように蒸留水で希釈したものを10mL調製した。大豆液状組成物又は精製大豆液状組成物を固相カートリッジに添加する前に、固相カートリッジOASIS HLB Plus（waters製）のコンディショニングを行なった。具体的には、OASIS HLB Plusにアセトニトリル5mLを添加し、次いで蒸留水5mLを添加した。
2. Determination of Tyr-DKPs in Soybean Liquid Composition and Refined Soybean Liquid Composition (1) Solid Phase Extraction of Soybean Liquid Composition and Purified Soybean Liquid Composition 10 mL of the product diluted with distilled water was prepared. Before adding the soybean liquid composition or the purified soybean liquid composition to the solid phase cartridge, the solid phase cartridge OASIS HLB Plus (manufactured by waters) was conditioned. Specifically, 5 mL of acetonitrile was added to OASIS HLB Plus, and then 5 mL of distilled water was added.
コンディショニング後の固相カートリッジOASIS HLB Plusに対し、Brix値を1に調製した大豆液状組成物又は精製大豆液状組成物を10mL添加し、次いで蒸留水5mLを添加した。その後、アセトニトリル3mLを添加し、溶出物を試験管に移し減圧濃縮した。その後減圧濃縮試料をジメチルスルホキシド1mLで溶解し、HPLC用試料とした。 To the OASIS HLB Plus after conditioning, 10 mL of a soybean liquid composition or a purified soybean liquid composition prepared with a Brix value of 1 was added, and then 5 mL of distilled water was added. Thereafter, 3 mL of acetonitrile was added, and the eluate was transferred to a test tube and concentrated under reduced pressure. Thereafter, the vacuum concentrated sample was dissolved in 1 mL of dimethyl sulfoxide to obtain a sample for HPLC.
（２）Tyr-DKPsのHPLC法での定量
HPLC：LC-2010 CHT（SHIMADZU製）
カラム：Devolesil C30 UG-5 (4.6mm x 150mm)（野村化学製）
移動相：バッファーA：0.1％ギ酸を含んだ蒸留水、
バッファーB：0.1％ギ酸を含んだ80%アセトニトリル蒸留水
グラジエントプログラム：
5%バッファーB/95%バッファーA →20%バッファーB/80%バッファーA
（リニアグラジエント：60分）
流速：1mL/min
検出波長：215nm
サンプル量：10μL/injection
標準品：cyclo (Ser-Tyr), cyclo (Asn-Tyr), cyclo (Tyr-Gly), cyclo (Tyr-Tyr),
cyclo (Leu-Tyr), cyclo (Val-Tyr), cyclo (Ile-Tyr), cyclo (Phe-Tyr)
上記条件で、HPLC用試料中のTyr-DKPsを測定し、大豆液状組成物及び精製大豆液状組成物中のTyr-DKPs量を求めた。結果を図１１〜１３に示す。
(2) Determination of Tyr-DKPs by HPLC
HPLC: LC-2010 CHT (manufactured by SHIMADZU)
Column: Devolesil C30 UG-5 (4.6mm x 150mm) (Nomura Chemical)
Mobile phase: Buffer A: distilled water containing 0.1% formic acid,
Buffer B: 80% acetonitrile distilled water containing 0.1% formic acid Gradient program:
5% buffer B / 95% buffer A → 20% buffer B / 80% buffer A
(Linear gradient: 60 minutes)
Flow rate: 1mL / min
Detection wavelength: 215nm
Sample volume: 10μL / injection
Standard products: cyclo (Ser-Tyr), cyclo (Asn-Tyr), cyclo (Tyr-Gly), cyclo (Tyr-Tyr),
cyclo (Leu-Tyr), cyclo (Val-Tyr), cyclo (Ile-Tyr), cyclo (Phe-Tyr)
Under the above conditions, Tyr-DKPs in the HPLC sample was measured, and the amount of Tyr-DKPs in the soybean liquid composition and the purified soybean liquid composition was determined. The results are shown in FIGS.
３．大豆液状組成物及び精製大豆液状組成物中のプリン体量の定量
（１）大豆液状組成物及び精製大豆液状組成物の過塩素酸分解
大豆液状組成物又は精製大豆液状組成物4.5mLを蓋付き試験管にとり、70％過塩素酸0.5mLと混合させ、ブロックヒーターを用いて95℃、60分間加熱して、加水分解させた。次いで、試験管を氷中に移し、8M 水酸化カリウム水溶液1mLを加え混合し、中和した。中和物を遠心チューブに移し、3500rpm、室温、10分間遠心し、得られた上清を、HPLC用試料とした。
3. Determination of purine content in soybean liquid composition and purified soybean liquid composition (1) Perchloric acid decomposition of soybean liquid composition and purified soybean liquid composition 4.5 ml of soybean liquid composition or purified soybean liquid composition is covered The sample was taken in a test tube, mixed with 0.5 mL of 70% perchloric acid, and hydrolyzed by heating at 95 ° C. for 60 minutes using a block heater. Next, the test tube was transferred to ice, and 1 mL of 8M aqueous potassium hydroxide solution was added and mixed to neutralize. The neutralized product was transferred to a centrifuge tube, centrifuged at 3500 rpm, room temperature for 10 minutes, and the resulting supernatant was used as a sample for HPLC.
（２）プリン体のHPLC法での定量
HPLC：LC-2010 CHT（SHIMADZU製）
カラム：Shodex Asahi GS-320 HQ (7.5mm x 300mm)（昭和電工製）
移動相：150mM リン酸ナトリウムバッファー（pH2.5）
グラジエントプログラム：アイソクラティック
流速：0.5mL/min
検出波長：260nm
サンプル量：10μL/injection
標準品：アデニン、グアニン、ヒポキサンチン、キサンチン
上記条件で、HPLC用試料中のプリン体量を測定し、大豆液状組成物及び精製大豆液状組成物中のプリン体量を求めた。結果を図１４〜１６に示す。
(2) Determination of purines by HPLC
HPLC: LC-2010 CHT (manufactured by SHIMADZU)
Column: Shodex Asahi GS-320 HQ (7.5mm x 300mm) (made by Showa Denko)
Mobile phase: 150 mM sodium phosphate buffer (pH 2.5)
Gradient program: Isocratic Flow rate: 0.5mL / min
Detection wavelength: 260nm
Sample volume: 10μL / injection
Standard products: adenine, guanine, hypoxanthine, xanthine Under the above conditions, the amount of purine in the HPLC sample was measured, and the amount of purine in the soybean liquid composition and the purified soybean liquid composition was determined. The results are shown in FIGS.
樹脂：大豆液状組成物＝1：1で精製した場合、全ての陽イオン交換樹脂で、単位Brixあたりのプリン体量の減少が確認された。また、単位BrixあたりのTyr-DKPs量の減少はほとんど認められず、アンバーライト200CT H AG、アンバーライト252NA及びアンバーライトFPC3500を用いた場合には、未処理群と比較して単位BrixあたりのTyr-DKPs量が増加しており、プリン体などの共雑物が除かれ、Tyr-DKPsの純度が増すことが示された。一方で、活性炭を用いて精製した場合は、単位Brixあたりのプリン体量及びTyr-DKPs量が著しく減少した。 When purified with a resin: soybean liquid composition = 1: 1, a decrease in the amount of purine per unit Brix was confirmed for all cation exchange resins. In addition, almost no decrease in the amount of Tyr-DKPs per unit Brix was observed, and when Amberlite 200CT H AG, Amberlite 252NA and Amberlite FPC3500 were used, Tyr per unit Brix compared to the untreated group -It was shown that the amount of DKPs was increased, the purine and other contaminants were removed, and the purity of Tyr-DKPs increased. On the other hand, when purified using activated carbon, the amount of purine bodies and the amount of Tyr-DKPs per unit Brix were significantly reduced.
樹脂：大豆液状組成物＝1：2で精製した場合、4種類の陽イオン交換樹脂で、単位Brixあたりのプリン体の減少が確認された。また、アンバーライト200CT H AG及びアンバーライトFPC3500を用いた場合には、未処理群と比較して単位BrixあたりのTyr-DKPs量が増加しており、プリン体などの共雑物が除かれ、Tyr-DKPsの純度が増すことが示された。一方で、活性炭を用いて精製した場合は、単位BrixあたりのTyr-DKPsが30％程度減少し、単位Brixあたりのプリン体の減少率を越える結果となった。 When purified with resin: soy liquid composition = 1: 2, reduction of purine bodies per unit Brix was confirmed with four types of cation exchange resins. In addition, when using Amberlite 200CT H AG and Amberlite FPC3500, the amount of Tyr-DKPs per unit Brix is increased compared to the untreated group, and contaminants such as purines are removed, It was shown that the purity of Tyr-DKPs is increased. On the other hand, when purified using activated carbon, Tyr-DKPs per unit Brix decreased by about 30%, exceeding the reduction rate of purine bodies per unit Brix.
樹脂：大豆液状組成物＝1：5で精製した場合、全ての陽イオン交換樹脂で、単位Brixあたりのプリン体の減少が確認された。 When purified with resin: soy liquid composition = 1: 5, it was confirmed that purine bodies per unit Brix decreased in all cation exchange resins.
また、図１７には大豆液状組成物の精製効率の指標として、陽イオン交換樹脂：大豆液状組成物比率を1：5として精製した場合のTyr-DKPs量/プリン体量比率を示した。 FIG. 17 shows the ratio of Tyr-DKPs / purine body when the ratio of cation exchange resin: soybean liquid composition is 1: 5 as an index of the purification efficiency of the soybean liquid composition.
陽イオン交換樹脂を用いて精製した場合は、未処理群、陽イオン交換樹脂処理群及び活性炭処理群と比べ、Tyr-DKP量/プリン体量の比率が増加しており、陽イオン交換樹脂は大豆液状組成物の精製に有効であることが実証された。 When purified using a cation exchange resin, the ratio of Tyr-DKP amount / purine body amount is increased compared to the untreated group, the cation exchange resin treatment group and the activated carbon treatment group. It has been demonstrated to be effective for the purification of soy liquid compositions.
実施例４：陽イオン交換樹脂処理による大豆液状組成物及び精製大豆液状組成物の色調変化
陽イオン交換樹脂処理により、褐色色素成分群が除去されたことを、マイクロプレートリーダーを用いて定量した。具体的には、96穴マイクロプレートに、水200μLと大豆液状組成物又は精製大豆液状組成物40μLを分注し混合後、490nmの吸光度を測定した。大豆液状組成物及び精製大豆液状組成物のBrix値は、デジタル屈折計RX-5000α（ATAGO）を用いて測定した。結果を図１８及び１９に示す。
Example 4: Change in color tone of soybean liquid composition and purified soybean liquid composition by cation exchange resin treatment The removal of brown pigment component groups by cation exchange resin treatment was quantified using a microplate reader. Specifically, 200 μL of water and 40 μL of soybean liquid composition or purified soybean liquid composition were dispensed and mixed in a 96-well microplate, and the absorbance at 490 nm was measured. The Brix value of the soybean liquid composition and the purified soybean liquid composition was measured using a digital refractometer RX-5000α (ATAGO). The results are shown in FIGS.
陽イオン交換樹脂を用いることにより、陰イオン交換樹脂を用いる場合よりも大豆液状組成物中の褐色成分を効率的に除去できることが示された。 It was shown that the brown component in the soybean liquid composition can be removed more efficiently by using the cation exchange resin than when using the anion exchange resin.
本発明は、ジケトピペラジン及びプリン体を含有する液状組成物を陽イオン交換樹脂と接触させ、その後、ジケトピペラジン含有液を回収することで、液状組成物中のジケトピペラジン含有量の低下は抑えられる一方、プリン体や色素夾雑物の含有量を低減することができる。従って、本発明では、ジケトピペラジン含有量が高く、プリン体や色素夾雑物の含有量が低い液状組成物を簡便な方法で提供できるため、産業上の利用可能性が高い。 The present invention reduces the diketopiperazine content in the liquid composition by bringing the liquid composition containing the diketopiperazine and purine into contact with the cation exchange resin and then recovering the diketopiperazine-containing liquid. While being suppressed, the content of purines and pigment contaminants can be reduced. Accordingly, in the present invention, a liquid composition having a high diketopiperazine content and a low content of purines and pigment contaminants can be provided by a simple method, so that the industrial applicability is high.
Claims (11)
前記接触工程後にジケトピペラジン含有液を回収する回収工程を含み、
前記接触工程における陽イオン交換樹脂と前記液状組成物との容積比率（陽イオン交換樹脂の容積：前記液状組成物の容積）が１：０．５〜１：１０であり、
前記接触工程において用いるジケトピペラジン及びプリン体を含有する液状組成物のｐＨが２．０〜６．０である、
ジケトピペラジン含有液状組成物の製造方法。 A contact step of bringing a liquid composition containing a diketopiperazine and purine into contact with a cation exchange resin, and a recovery step of recovering a diketopiperazine-containing liquid after the contact step,
The volume ratio of the cation exchange resin and the liquid composition in the contact step (volume of the cation exchange resin: volume of the liquid composition) is 1: 0.5 to 1:10,
The pH of the liquid composition containing diketopiperazine and purine used in the contacting step is 2.0 to 6.0.
A method for producing a diketopiperazine-containing liquid composition.
Ｂｒｉｘあたりのジケトピペラジンの総量が、１０００μｇ／１００ｇ／Ｂｒｉｘ以上である、前記ジケトピペラジン含有液状組成物。 A diketopiperazine-containing liquid composition obtained by the production method according to any one of claims 1 to 8,
The diketopiperazine-containing liquid composition, wherein the total amount of diketopiperazine per Brix is 1000 μg / 100 g / Brix or more.
前記液状組成物と陽イオン交換樹脂とを接触させる接触工程、及び
接触工程後にジケトピペラジン含有液を回収する回収工程を含み、
前記接触工程における陽イオン交換樹脂と前記液状組成物との容積比率（陽イオン交換樹脂の容積：原料エキスの容積）が１：０．５〜１：１０であり、
前記接触工程において用いるジケトピペラジン及びプリン体を含有する液状組成物のｐＨが２．０〜６．０である、
前記方法。 A method for reducing the content of purine and pigment contaminants from a liquid composition containing diketopiperazine, purine and pigment,
A contact step of bringing the liquid composition into contact with the cation exchange resin, and a recovery step of recovering the diketopiperazine-containing liquid after the contact step,
The volume ratio of the cation exchange resin and the liquid composition in the contact step (volume of cation exchange resin: volume of raw material extract) is 1: 0.5 to 1:10,
The pH of the liquid composition containing diketopiperazine and purine used in the contacting step is 2.0 to 6.0.
Said method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014250414A JP6487688B2 (en) | 2014-12-10 | 2014-12-10 | Method for producing liquid composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014250414A JP6487688B2 (en) | 2014-12-10 | 2014-12-10 | Method for producing liquid composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016113367A true JP2016113367A (en) | 2016-06-23 |
| JP6487688B2 JP6487688B2 (en) | 2019-03-20 |
Family
ID=56140962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250414A Active JP6487688B2 (en) | 2014-12-10 | 2014-12-10 | Method for producing liquid composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6487688B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020081518A1 (en) * | 2018-10-15 | 2020-04-23 | Nitto Denko Corporation | Methods for reducing purine levels in fluid mixtures |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11504224A (en) * | 1996-02-26 | 1999-04-20 | ザ プロクター アンド ギャンブル カンパニー | Green tea extract subjected to cation exchange treatment and microfiltration to improve clarity and color |
| JP2004275091A (en) * | 2003-03-17 | 2004-10-07 | Asahi Breweries Ltd | Method for producing fermented malt beverage and active carbon for removing purines from fermented malt beverage |
| JP2004321004A (en) * | 2003-04-21 | 2004-11-18 | Asahi Breweries Ltd | Method for producing fermented malt beverage |
| JP2011152058A (en) * | 2010-01-26 | 2011-08-11 | Asahi Breweries Ltd | Method for modifying yeast extract |
| WO2012008100A1 (en) * | 2010-07-15 | 2012-01-19 | アサヒビール株式会社 | Soft drink, fermented malt drink, and method for removing purines in wort |
| WO2013094494A1 (en) * | 2011-12-21 | 2013-06-27 | 花王株式会社 | Method for producing purified tea extract |
| JP2013135650A (en) * | 2011-12-28 | 2013-07-11 | Japan Organo Co Ltd | Method for adjusting liquid food or drink |
| JP2013135649A (en) * | 2011-12-28 | 2013-07-11 | Japan Organo Co Ltd | Method for adjusting liquid food or drink |
-
2014
- 2014-12-10 JP JP2014250414A patent/JP6487688B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11504224A (en) * | 1996-02-26 | 1999-04-20 | ザ プロクター アンド ギャンブル カンパニー | Green tea extract subjected to cation exchange treatment and microfiltration to improve clarity and color |
| JP2004275091A (en) * | 2003-03-17 | 2004-10-07 | Asahi Breweries Ltd | Method for producing fermented malt beverage and active carbon for removing purines from fermented malt beverage |
| JP2004321004A (en) * | 2003-04-21 | 2004-11-18 | Asahi Breweries Ltd | Method for producing fermented malt beverage |
| JP2011152058A (en) * | 2010-01-26 | 2011-08-11 | Asahi Breweries Ltd | Method for modifying yeast extract |
| WO2012008100A1 (en) * | 2010-07-15 | 2012-01-19 | アサヒビール株式会社 | Soft drink, fermented malt drink, and method for removing purines in wort |
| WO2013094494A1 (en) * | 2011-12-21 | 2013-06-27 | 花王株式会社 | Method for producing purified tea extract |
| JP2013135650A (en) * | 2011-12-28 | 2013-07-11 | Japan Organo Co Ltd | Method for adjusting liquid food or drink |
| JP2013135649A (en) * | 2011-12-28 | 2013-07-11 | Japan Organo Co Ltd | Method for adjusting liquid food or drink |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020081518A1 (en) * | 2018-10-15 | 2020-04-23 | Nitto Denko Corporation | Methods for reducing purine levels in fluid mixtures |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6487688B2 (en) | 2019-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7121059B2 (en) | Plant extract containing diketopiperazine and method for producing the same | |
| CN107846939B (en) | Method for producing polysaccharide-protein complex | |
| KR101110095B1 (en) | Seasoning having function of imparting body | |
| JP6683735B2 (en) | Beer taste beverage | |
| EP3027055B1 (en) | Potato derived flavour enhancing composition and method for the manufacture thereof | |
| JPWO2017168718A1 (en) | Container drink | |
| JP6487688B2 (en) | Method for producing liquid composition | |
| Repajic et al. | Influence of cultivar and industrial processing on polyphenols in concentrated sour cherry (Prunus cerasus L.) juice | |
| WO2017168717A1 (en) | Packaged beverage | |
| TWI664911B (en) | Essence of dried fish having excellent taste and method for producing same | |
| JP2000316523A (en) | Production of yeast extract | |
| JP7182742B1 (en) | Grain tea beverage containing enzymatic decomposition product of sesame protein | |
| JP6683736B2 (en) | Packaged beverages | |
| JP2003310161A (en) | Method for producing strictinin-containing tea beverage and method for storing the same | |
| Repajić et al. | Utjecaj sorte i industrijske obrade na sastav polifenola u koncentriranom soku višnje (Prunus cerasus L.) | |
| JP2003321489A (en) | Method for recovering strictinin, method for storing strictinin-containing material, method for quantifying strictinin | |
| NZ715250B2 (en) | Plant extract containing diketopiperazine and method for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180802 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190111 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190222 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6487688 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |